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ABSTRACT

Aim
To assess  the change in  expression of various tumour markers (p53, mcm2 and cyclin D1) with change in internal endocrine environment in patients with primary breast cancer and to study the expression and prognostic association of cyclin D1 and replication licensing proteins (mcm2 and geminin) in invasive breast cancer.

Hypothesis
 The endocrine environment may be critical in the development and efficacy of treatment in breast cancer. Oestrogen has the potential to modulate the function of p53 network and cell cycle proteins (cyclin D1) in breast cancer, the consequences of which could profoundly affect treatment efficacy. It is proposed that the serum oestrogen level may effect the measurement of protein markers in primary breast cancer.
It is hypothesised that the replication licensing protein family, mcm, may be a more consistent marker of proliferation than the conventional immunohistochemical marker, Ki-67, in primary breast cancer.


Material and Methods
Women with a diagnosis of primary, operable, symptomatic breast cancer were eligible and a total of 99 patients (47  premenopausal and 52  postmenopausal) were included in the study.  Of these, 30 pre-menopausal and 33 post-menopausal women had paired samples of breast cancer biopsy and venous blood taken at diagnosis and later at the time of resectional surgery. The samples were collected at two time points to study the change in expression of tumour proteins, if any, with the change in serum oestradiol levels in pre-menopausal women, the postmenopausal women served as the control.  The rest of the patients included had tissue samples and blood taken at one time point only i.e. at resectional surgey. Samples comprised formalin fixed breast cancer tissues from both time points for immunohistochemistry and FISH; serum was drawn for 17- oestradiol, progesterone, FSH, LH. Tumour micro-arrays were prepared from the surgical specimens (corresponding to the second time point) and whole tissue sections were used to study the diagnostic specimen (corresponding to the first time point).

Results
Overexpression of cyclin D1 was seen in 63% of cancers studied whilst CCND1 amplification was identified in 30%. CCND1 amplification was significantly associated with cyclin D1 protein overexpression (p<0.001; Fisher’s exact test) and both CCND1 amplification and cyclin D1 protein expression with oestrogen receptor (ER) expression (p=0.003 and p<0.001; Fishers exact test). Neither CCND1 amplification nor cyclinD1 expression was associated with tumour size, pathological node status or HER2 amplification. High CCND1 amplification (CNG > 8) was significantly associated with high tumour grade and higher Nottingham Prognostic Index (p=0.001). 
 Increased expression of both Mcm2 and geminin was associated with high tumour grade (p<0.05 ANOVA). Mcm2: Ki-67 and geminin: Ki-67 ratios were similar across different tumour grades suggesting similar G1 transit time in different grades of tumour, with higher grade tumours containing a larger proportion of in-cycle cells with proliferative potential. Expression of Mcm2 and geminin was associated with a high Nottingham Prognostic Index NPI (p<0.001, Spearman correlation) and inversely with ER-positive tumours (p<0.0001, t-test), hence correlated with poor prognosis. 
We explored a potential change in p53 expression with change in serum oestradiol levels in premenopausal women, following the generation of hypothesis from an animal study done in MCF-7 mouse xenograft model. The observation from MCF7 xenograft model suggesting an inverse relationship between p53 expression and serum oestradiol did not hold good in humans, although the numbers tested were small.

Conclusion
High level CCND1 amplification could be used to identify a subset of ER-positive breast cancers that are associated with poor prognosis. Such patients could be offered adjuvant chemotherapy, in keeping with evidence that CCND1 amplified cancers respond poorly to endocrine agents. 
This study demonstrates that replication licensing factors; Mcm2 and geminin correlate with poor prognosis (ER-negative and high NPI) breast cancers, and therefore merit consideration as poor prognostic markers in breast cancer. 
We did not observe any significant change in expression of p53 protein with a change in serum oestradiol levels in premenopausal patients with primary invasive breast cancer.












CHAPTER-1
INTRODUCTION














Hypothesis 
1.	The endocrine environment may be critical in the development and efficacy of treatment in breast cancer. Oestrogen has the potential to modulate the function of p53 network and cell cycle proteins (cyclin D1) in breast cancer, the consequences of which could profoundly affect treatment efficacy. It is proposed that the serum oestrogen level may effect the measurement of protein markers in primary breast cancer.
2.	Methods for predicting and assessing tumour behaviour include assessment of proliferation. It is hypothesised that the replication licensing protein family, mcm, may be a more consistent marker of proliferation than the conventional immunohistochemical marker, Ki-67, in primary breast cancer. 

Questions
1.	How do the expression of cyclin D1 and replication licensing proteins relate to the prognosis of breast cancer and what are their potential therapeutic implications?
2.	Does expression of proteins critical to cell cycle (licensing proteins and cyclin D1) or response to therapy (p53 network) relate to the internal endocrine environment (menopausal status, plasma oestrogen)?
3.	Does the expression of p53 network proteins and cyclin D1 vary in the same (untreated) breast cancer in sequential biopsies over time?


Background

Cyclin D1

The p16-cyclinD1-cdk4-Rb pathway is central to the regulation of the G1-S phase transition in the cell cycle (Fig-1) and alteration or mutation of one of the components of this pathway, the most prominent being cyclin D1, is encountered in most human cancers (Motokura, Bloom et al. 1991; Jiang, Kahn et al. 1992; Schuuring, Verhoeven et al. 1992). Cyclin D1 plays a pivotal role in oestrogen-induced breast cancer with oestrogen action mediated through transcriptional activation of cyclin D1 and c-myc (Altucci, Addeo et al. 1996; Foster and Wimalasena 1996; Prall, Rogan et al. 1998). This evidence suggests a critical role for cyclin D1 in human breast cancer cell-cycle control. Given this role, overexpression of cyclin D1 may provide a growth advantage to the tumour cells and may also contribute towards resistance to endocrine therapy (Musgrove, Lee et al. 1994). Cyclin D1 can also regulate the growth of oestrogen-responsive tissues by activating the oestrogen receptor (ER) in a ligand-independent fashion i.e. in the absence of oestrogen (Zwijsen, Wientjens et al. 1997). It is thus logical to explore the expression of cyclin D1 at the protein level and amplification at the genetic level in invasive breast cancer to assess the a) relation to the internal endocrine environment and b) potential prognostic and therapeutic value.



Replication licensing proteins

Regulation of the precise duplication of chromosomal DNA in each cell cycle requires a protein complex, mcm2-7, assembling onto the replication origins of the DNA. This replication system is directly controlled by cyclin dependent kinases and a small inhibitor named geminin. Mcm2-7 has been suggested as a functional marker of the proliferative ans non-proliferative states (Blow and Hodgson 2002). Cells that withdraw from the cell cycle, either reversibly (into the G0 state) or irreversibly (such as terminal differentiation or senescence) degrades mcm2-7. Re-entry into the cell cycle from G0 requires resynthesis of mcm2-7. In breast tissues and breast cancer, a high proportion of mammary acinar cells express mcm proteins compared with conventional proliferation markers, suggesting these cells are being held in a state of ‘in-cycle arrest’ (Stoeber, Tlsty et al. 2001). This atypical mode of cell cycle arrest may affect both the mechanism of tumorigenesis and the response to therapy. The ability of mcm to recognise the potentially replicable cells in addition to the replicating cells suggests it may be a better diagnostic, prognostic and monitoring candidate in comparison with the conventional markers such as Ki-67.


p53 network

Many chemotherapeutic agents act via p53 to induce cancer cell death. However, the relationship between p53 expression, p53 mutation and the response of breast cancer to anthracyclin-based therapy remains controversial (Aas, Borresen et al. 1996; Bertheau, Plassa et al. 2002).
p53 and oestrogen receptor proteins are important regulatory proteins involved in the pathogenesis of breast cancer. Loss of p53 wild-type activity is seen in up to 25% of primary breast cancers (Ziyaie, Hupp et al. 2000). Two-thirds of breast cancers express oestrogen receptor-alpha (ER) that recognises oestrogen as a mitogen. However, although a physical interaction between p53 and ER has been suggested, the link between the serum 17- oestradiol and p53 activity has not been explored in patients with breast cancer.

Studies performed in vitro on MCF7 and T47D breast cancer cell lines (Molinari, Bontempo et al. 2000; Moudgil, Dinda et al. 2001; Okumura, Saji et al. 2002) have shown that oestradiol up-regulates p53 expression. However, these cell lines require oestrogen for growth so it is difficult to determine whether the increased p53 expression is a consequence of oestrogen induced cell replication or a direct effect of oestrogen supplementation. However, an inverse relationship between p53 protein expression and serum oestrogen shown by an in vivo study on MCF7 xenografts (Ziyaie D 2000; Ziyaie D 2001) conducted in Dundee has highlighted the importance of the serum oestrogen concentration as an adjunct to p53 expression in vivo. This also indicates a possible dual role of action for oestrogen acting not only as a true mitogen but also modifying tumour behaviour. If this is borne out in humans, then the timing of chemotherapy in relationship to serum and tissue/tumour oestradiol could influence the effectiveness of anti-cancer agents particularly in pre-menopausal patients.

Aims

1.	To study the expression of cyclin D1 (at protein and DNA level) and replication licensing proteins (mcm and geminin) in invasive breast cancer.
2.	To assess the prognostic potential of cyclin D1 and replication licensing proteins (mcm and geminin) in invasive breast cancer.
3.	To elucidate the differences in expression of tumour proteins (p53, cyclin D1, Ki67) in relation to the internal endocrine environment in pre-menopausal women with breast cancer. 










CHAPTER-2
REVIEW OF THE LITERATURE





Breast cancer
	
Breast cancer is the most common cancer among women and is the second most common cause of death from cancer in women (after lung cancer). Approximately 1 million women are diagnosed with breast cancer every year worldwide (Ferlay J 2004) and breast cancer accounts for the most common cause of death in women aged 40-50 years in the UK. There has been a 12% increase in age-standardised incidence of breast cancer in UK over the last decade (ISD 2007; Statistics 2007).

Overview of aetiology

The aetiology of breast cancer is multifactorial, the two major influences being the hormonal environment and the genetic basis.
1)	Endocrine influences:  
The hormonal regulation of cyclical stimulation followed by involution of breast epithelium predisposes to the risk of breast cancer. A common thread linking the main risks for developing breast cancer in women is cumulative, excessive exposure to oestrogen either from endogenous or exogenous sources. The various risk factors are listed below.
a)	Age at menarche (younger age increases the risk) (Clavel-Chapelon 2002).
b)	Age at menopause (menopause at age 55 doubles the risk compared to menopause at age 45)(Kelsey, Gammon et al. 1993).
c)	Age at first pregnancy (if over 30 increases the risk 2 times compared to age less than 20 at first pregnancy) (Bertheau, Plassa et al. 2002) (Ewertz, Duffy et al. 1990).
d)	Number of pregnancies (higher number is protective) (Kelsey, Gammon et al. 1993).
e)	Breast-feeding history (Breast feeding is protective)(Bertheau, Plassa et al. 2002).
f)	Oral contraceptive use : Risk is elevated during and for 10 years after use (1996). This epidemiological polled study suggested that high oestrogen pills increase risk, low oestrogen/progesterone pill is safer and use before age of 20 increases risk. However, there is evidence to suggest that newer contraceptive pills does not increase breast cancer risk in current or previous users (Marchbanks, McDonald et al. 2002), which would be in line with the previous evidence that low estrogen dose pills are safer.
g)	Hormone replacement therapy (HRT): A recent analysis of pooled published data on HRT and risk of breast cancer has shown that the relative risk for current users being 1.66 and risk increases with duration of use (especially with >10 years of use). The effect is substantially greater for oestrogen-progestagen combinations than for oestrogen only HRT (Beral 2003). The risk returns to normal levels five years after cessation of HRT (1997). Cancers diagnosed in women on HRT tend to be earlier stage and hence HRT is not associated with increased breast cancer mortality. Breast cancer risk from HRT should be balanced against the benefits of HRT including those on the cardiovascular system and bones.

2) Genetics
a) Familial predisposition: About 5-10% of breast cancer in the West is attributed to genetic predisposition. Only 25% of these are due to the known highly penetrant genes such as BRCA1 and BRCA2 and the rest is due to genetic variations conferring moderate risk.
BRCA1 (17q) (Miki, Swensen et al. 1994) and BRCA2 (13q) (Wooster, Bignell et al. 1995) account for many of the families with multiple (four or more) breast and other cancers in close relatives. Within certain populations, a particular mutation identified (e.g. BRCA2 deletion at position 999 in half of familial cancers in Iceland) demonstrates the genetic lines of inheritance (Rafnar, Benediktsdottir et al. 2004). Men with BRCA1 mutations also have an increased risk of developing breast cancer. Additionally, BRCA1 mutations are associated with an increased risk of pancreatic cancer. Mutations in the BRCA2 gene are associated with an increased chance of developing male breast cancer and cancers of the prostate and pancreas. An aggressive form of skin cancer called melanoma is also more common among people who have BRCA2 mutations.
The less common ones are Li-Fraumeni Syndrome (inheritance of mutant p53) and Cowden’s Syndrome (PTEN). These genes have comparatively high penetrance resulting in multiple cancer sites within each family and sometimes within each individual. The breast cancers usually occur before the age of 45 years and may be bilateral. 
It was proposed that breast cancer susceptibility is largely ‘polygenic’: that is, susceptibility is conferred by a large number of loci, each with a small effect on breast cancer risk (Pharoah, Antoniou et al. 2008). This model is consistent with the observed patterns of familial aggregation of breast cancer. Some research have identified variants of the DNA repair genes such as ATM, BARD1, BRIP1, CHEK2, PALB2  that confer twofold risk of breast cancer but these are rare in population (Meijers-Heijboer, van den Ouweland et al. 2002; Erkko, Xia et al. 2007). Of these genes, ATM (Thompson, Duedal et al. 2005) and CHEK2 (2004) have the strongest evidence of being related to the risk of developing breast cancer. 

Recent Genome Wide Association Studies (GWAS) (Easton, Pooley et al. 2007) have confirmed the existence of several common genetic variants affecting breast cancer risk, one of the susceptibility loci being FGFR2. GWAS allow hundreds of thousands of single nucleotide polymorphisms (SNPs) to be analysed in association studies, thus providing a basis for identifying moderate risk alleles without prior knowledge of position or function. It has also been shown that some low penetrance variants may influence cancer phenotype and prognosis e.g. mdm2 SNP309 accelerates tumour formation in a hormone-dependent manner (Bond, Hirshfield et al. 2006).
Noninherited (somatic) mutations also have been identified in breast tumors. For example, somatic mutations in the ERBB2 (also called Her-2/neu), DIRAS3, and TP53 genes have been associated with some cases of breast cancer.

b) Molecular markers: There appears to be a wide range of molecular abnormalities in breast cancer, which probably interact with the cellular environment and play a role in aetiology, development, invasion and metastasis of breast cancer. The ones with widespread clinical utility include ER (Hammond, Hayes et al. 2010) and HER2 (Burandt and Sauter), ER expression correlates with survival and response to endocrine therapy and HER2 besides being a poor prognostic factor forms a target for biological therapy in HER-overexpressing tumours (Rody, Loibl et al. 2006). 

p53: p53 is a tumour suppressor gene that mediates the cellular responses to injury with subsequent cell cycle arrest or apoptosis. About 25% breast cancers are associated with the presence of mutant p53 and these usually carry a poor prognosis and are resistant to treatment by chemotherapy (Ziyaie, Hupp et al. 2000; Olivier, Langerod et al. 2006). Thus detection of p53 mutation may be important in clinical therapeutic decision making.  

ER: Oestrogen receptor (ER) status is assessed by immunohistochemistry on tissue sections, for which a variety of scoring systems exist. Two forms of ER exist: ER alpha (detected and measured clinically in breast cancer samples) (Ali and Coombes 2000) and ER beta (Mosselman, Polman et al. 1996) (of uncertain significance in breast cancer). Tumours with moderate or high ER are much more likely to respond to endocrine therapy than those with no or low ER (Millis 1980; Vollenweider-Zerargui, Barrelet et al. 1986; Chevallier, Heintzmann et al. 1988).  In addition, ER expression correlates with survival, at least in the first 5 years following diagnosis.  However, only two-third of patients with ER expression appear to have an intact, functioning down stream effector pathways which is assessed by detecting progesterone receptor (PgR) on immunohistochemical sections.  Expression of PgR along with ER suggests the cancer is more likely to respond to endocrine therapy (Rutqvist, Cedermark et al. 1989). 
Endocrine resistance in ER-positive breast cancer has not been completely understood. Several underlying mechanisms have been proposed such as HER2 overexpression inducing tamoxifen resistance (Osborne, Shou et al. 2005), low expression of bcl2 associated with tamoxifen failure and early relapse (Vendrell, Robertson et al. 2008)

HER2 (Human epidermal growth factor receptor): HER2 (erbB2, neu) is a transmembrane growth factor receptor, expressed in 15%-30% of invasive breast cancer (and, for reasons which are unclear, up to 80% of DCIS) and associated with poor prognosis in invasive breast cancer (Slamon and Clark 1988).  It is one of a family of growth factor receptors (including epidermal growth factor receptor EGFR, erb-1, erbB3 and erbB4) but unlike most other molecular markers now forms a target for “biological therapy”.  For patients in whom HER2 is amplified ie multiple copies for the gene best detected by flourescence in situ hybridisation, FISH (Bartlett, Mallon et al. 2003) and is overexpressed (on immunohistochemistry), humanised mouse antibody, trastuzumab (herceptin) is the first “new” biological therapy to enter clinical use (Saeki and Takashima 2003; Tomadoni, Lombardo et al. 2004).  What is perhaps of greatest clinical significance is that this therapy may be most effective in node positive patients with invasive breast cancer whose disease is relatively insensitive to chemotherapy or endocrine therapy (Cardoso, Durbecq et al. 2004) . 

Other genes: Various genes like apoptotic pathway genes (bcl-2, bax), tumour suppressor genes (Rb), oncogenes (c-myc), growth factors (TGF, TGF , epidermal growth factor), proteases (cathepsin D) and cell cycle related genes (p21, cyclin D) and oestrogen receptors (ER) have been studied with respect to the aetiology of breast cancer.

Physiology of Oestrogen Hormone

Synthesis  
Oestrogens are steroid hormones derived from cholesterol, which is modified by series of enzymic conversions (Fig-2.1). The predominant oestrogen secreted by the ovarian follicle is oestradiol-17, which functions as a circulating hormone to act on distal tissues. The theca interna cells of the ovarian follicle synthesize androgenic steroids that form the precursor for oestrogen synthesis. These androgens diffuse to the adjacent granulosa cells where they are converted to oestradiol-17, via the aromatase enzyme present in these cells. Oestrone is produced largely by peripheral conversion from oestradiol and androstenedione. Oestriol is the weakest of all the naturally occurring oestrogens and is formed in the liver as a conversion product of oestradiol and oestrone.

	Cholesterol

	
	Pregnenolone				Progesterone

									Pregnanediol
17-hydroxypregnenolone		17-hydroxyprogesterone


Dehydroepiandrosterone		Androstenedione

Androgens
Androstenediol			Testosterone
Aromatase

Oestradiol-17			Oestrone
Oestrogens			
						Oestriol


Fig-2.1:Pathway for oestrogen synthesis (Russell 1995). 17-oestradiol is the principal oestrogen secreted by the ovary. Oestriol and oestrone are weak naturally occurring oestrogens.


Hormonal patterns during the menstrual cycle 

A series of cyclical changes in gonadal hormone production characterize adult ovarian function, which results from cyclic changes in pituitary gonadotropins (Fig-2.2) (Genuth 1998). Plasma FSH and LH levels are at their lowest levels towards the end of the luteal phase (a few days before the onset of menstrual bleeding). The FSH levels begin to rise just before the onset of menses, followed somewhat later by a rise in LH levels. The oestrogen (oestradiol and oestrone) levels increase gradually, stimulated by the rise in the FSH in the first half of menstrual cycle. Progesterone remains at relatively low, constant levels. 
During the second half of the follicular phase, FSH levels fall modestly, whereas LH levels continue to rise slowly. The oestrogens rise sharply and reach a peak just before the ovulation and the progesterone levels begin to rise at this stage.
A very sharp spike in plasma gonadotropins marks the ovulatory phase. Plasma oestradiol levels plummet from their peak at the same time that FSH and LH are on their ovulatory upswing.
After ovulation, LH and FSH both continue to decline during the luteal phase, and reach their lowest points toward the end of the cycle. This phase is characterized by a tenfold increase in the progesterone level. Oestrogens also increase, and broad peak occur during the middle of luteal phase.
In post-menopausal women, oestrogen levels are low but could be variable, FSH>25U/l and LH>15U/l, with FSH higher than LH, are consistent with menopause (in normal cycles, LH levels are usually higher than FSH).




Fig-2.2: Plasma hormone levels throughout the menstrual cycle (Genuth 1998).




Menopausal Staus	Oestradiol (pmol/L)	Progesterone (nmol/L)	FSH(U/L)	LH(U/L)
Pre-menopausal	Follicular Phase	184-532	<3.18	3-20	2-15
	Mid cycle peak	411-1626		9-26	22-105
	Luteal phase	184-885	9.5-63.6	1-12	0.6-19
Postmenopausal	<217	0-15	18-153	16-64

Table-1.1: Normal ranges of serum hormone levels (Fischbach 1998)

					



Endocrine consequences of the menopause 
The cause of the menopause is primary ovarian failure due to follicular depletion. The hypothalamopituitary gonadotropin mechanism is still operative and so the secretion of LH and FSH increase because of the loss of feedback inhibition by ovarian hormones. The circulating levels of FSH and LH are increased, compared with the early follicular phase of the menstrual cycle, about 13- and 3-fold, respectively (Russell 1995). 
The concentration of oestradiol-17 in plasma is as low as in the early follicular phase of the menstrual cycle. In postmenopausal women, oestrone is the dominant plasma oestrogen, which is derived from the conversion of adrenocortical androstenedione in peripheral tissues (mainly the liver). The circulating levels of oestrogens in postmenopausal women are not the drivers of oestrogen action, because oestrogens are produced in a number of extragonadal sites (by aromatase enzymes) and acts locally at these sites as a paracrine or intracrine factor. These sites include the mesenchymal cells of adipose tissue (including that of breast), osteoblasts and chondrocytes of bone, vascular endothelium, and numerous sites in the brain. Thus, the oestrogen involved in breast cancer development in postmenopausal women is not primarily circulating oestrogens but that which is produced locally in the breast (Simpson 2003).


Oestrogen and breast carcinogenesis

Oestrogens have been linked to the development and progression of breast cancer and there is considerable evidence, both experimental and epidemiologic, that establishes this causative link.
1.	Epidemiological studies have shown that prolonged exposure to oestrogen, i.e. early menarche, late menopause and oestrogen replacement therapy, is a risk factor for breast cancer (Clemons and Goss 2001).
2.	Oophorectomy can lead to regression of breast cancer in premenopausal women, an  observation originally  made by Sir George Thomas Beatson of Glasgow and applied it clinically for the control of inoperable breast cancer in premenopausal women in 1895 (Macmahon and Cahill 1976).
3.	In vitro experiments have also indicated that the breast cancer cells grow in response to oestrogen administration (Foster, Henley et al. 2001).
4.	Various experimental models have shown that oestrogen is required (possibly an absolute requirement) for both the initiation and progression of some breast cancers (Henderson, Ross et al. 1988), (Soule and McGrath 1980).
5.	The efficacy of the endocrine therapies such as tamoxifen in decreasing the disease progression and in the development of contralateral breast cancer underlines the essential role of regulation of cell proliferation in breast cancer (Sutherland, Reddel et al. 1983).

The level of oestrogen receptor expression is higher in patients with breast cancer than in normal breast epithelium and this upregulation of ER could be the reason for a strong mitogenic effect of oestradiol (E2) on breast cancer in contrast to the minimal effect on normal epithelium (King 1993). It is also hypothesized that carcinogenesis may be accompanied by increased sensitivity to oestrogen, which provides a growth advantage to the tumour by maximizing use of the low oestrogen concentrations encountered in the postmenopausal state (King 1993). 

It has been observed that the proliferation rate is higher in ER-positive benign proliferative lesions in contrast to ductal carcinomas (both in situ and invasive), where ER-negative cases have a higher proliferation rate (Schmitt 1995). The observation of higher rates of proliferation in ER-positive benign lesions fits with the concept of an initial hormone-dependent status in breast carcinogenesis. The activation of ER by oestrogens increases the possibility of cells undergoing malignant transformation. The demonstration of a higher proliferation rates in ER-negative carcinomas, from the in situ phase onwards, suggests that breast cancer progression is paralleled by progressive hormone independence. However, the absence of ER immunoreactivity in several cases of breast carcinoma does not imply a true ER negativity because many breast tumours produce defective forms of ER (Miksicek 1994). These ER variants have the capacity to stimulate the expression of steroid responsive genes such as pS2 even in the absence of hormone so breast cancer cells that express ER variants proliferate as if they are chronically stimulated by oestrogen. The emergence of ER variants were thought to be responsible for tumours exhibiting hormone independence, increased proliferation and tamoxifen resistance, however the clinical evidence is lacking (Dowsett 1996; Tonetti and Jordan 1997).

There is evidence that oestrogen metabolites may have genotoxic potential. The oestrogens may be metabolized via catechols (2- or 4-hydroxy oestradiol or hydroxyoestrone) into reactive quinines, which can directly damage DNA, initiating carcinogenesis (Yager 2000). It was observed that a polymorphism associated with a low-activity form of catechol-O-methyltransferase, an enzyme involved in the inactivation of catechol oestrogens, is associated with an increased risk for developing breast cancer (Lavigne, Helzlsouer et al. 1997).

Molecular events in oestrogen action
Earlier studies showed that E2 increases the rate of cell proliferation by both recruiting non-cycling cells into the cell cycle and by shortening the overall cell cycle time due to a reduction in the length of G1 phase (Sutherland, Reddel et al. 1983; Leung and Potter 1987). This was further supported by the observations that antiestrogens arrest ER-positive breast cancer cells in G1 phase (Wakeling, Dukes et al. 1991; Watts, Brady et al. 1995).
There is evidence in the literature that the mitogenic effects of E2 are mediated by at least two E2 target genes, c-myc (Dubik and Shiu 1992) and cyclin D1 (Altucci, Addeo et al. 1996; Said, Conneely et al. 1997; Tong and Pollard 1999), each working independently (Prall, Rogan et al. 1998). Of the two regulatory genes, myc is activated earlier than cyclin D1 in G1 phase by E2 (Prall, Sarcevic et al. 1997). These pathways converge at the activation of cyclin E-Cdk2 complexes. The active cyclin E-Cdk2 complexes are depleted of the cyclin dependent kinase (Cdk) inhibitor p21 (waf1/cip1) because of oestrogen-mediated inhibition of transcription of p21 (Planas-Silva and Weinberg 1997; Prall, Carroll et al. 2001) and/or sequestration of Cdk inhibitors by cyclin D1. Phosphorylation of pRB (retinoblastoma) follows in response to activation of cyclin E-Cdk2 and cyclin D-Cdk4 complexes, resulting in the release of transcription factors necessary for DNA synthesis and progression from G1 to S phase of the cell cycle (Foster and Wimalasena 1996; Doisneau-Sixou, Sergio et al. 2003).
While E2 induces myc through the ER(oestrogen receptor)-mediated signalling pathway by binding to the ERE (oestrogen response element) present in the promoter region of myc (Dubik and Shiu 1992), the cyclin D1 gene (CCND1) is not known to contain an ERE region in its promoter (Sabbah, Courilleau et al. 1999; Foster, Henley et al. 2001) and CCND1 activation is probably mediated through protein-protein interactions. However, the role of additional non-ER pathway(s) has also been suggested in the oestrogen-dependent tumour growth (Felty, Singh et al. 2005). Recently, it has been suggested that E2-induced mitochondrial reactive oxygen species (ROS) play a role in G1/S progression of oestrogen-stimulated breast cancer cells. Previous studies have shown that the expression of early G1 (phase) genes, c-myc, c-fos, c-jun, and CCND1 (Cyclin D1) are regulated by ROS (Janssen, Matalon et al. 1997; Galli, Labato et al. 2003) and E2-induced ROS activate transcription factors such as AP-1, which is known to be involved in the transcription of cell cycle gene, cyclin D1 (Galli, Labato et al. 2003). Also, blockers of mitochondrial function blocked E2-induced cell cycle progression, which was accompanied by decreased expression of cyclins D and E, thereby suggesting that in addition to ER signalling pathway, E2-induced mitochondrial ROS contribute to G1/S phase progression of oestrogen-stimulated breast cancer cells (Felty, Singh et al. 2005).




Oestrogen Receptors (ER)

Structure and function

The effects of oestrogens are mediated by ligand-activated transcription factors called oestrogen receptors (ER), members of the nuclear receptors superfamily, and two forms of the ER have been identified,  and . Structurally, the oestrogen receptor can be subdivided into several functional domains. There is a highly conserved DNA-binding domain (region designated C in Fig-2.3) containing two zinc fingers, which are involved in specific DNA binding and receptor dimerization, and a less well conserved ligand-binding domain (LBD or E/F region) harbouring regions for ligand-binding, receptor dimerization, nuclear localization and interactions with transcriptional coactivators and corepressors. The LBD also harbours activation function (AF-2), which is a complex region whose structure and function are governed by the binding of ligands. The N-terminal A/B domain is highly variable in sequence and length and usually contains a ligand-independent activation function (AF-1), which activates target genes by directly interacting with components of the core transcriptional machinery or with coactivators that mediate signalling to downstream proteins. The hinge domain (D region) contributes flexibility to the DNA-versus the ligand-binding domain. Finally, the C-terminal F domain contributes to the transactivation capacity of the receptor (Hurd C 1998; Nilsson, Makela et al. 2001). 
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Fig-2.3: Primary domain structure of human oestrogen receptor.



ER and ER have a high degree of conservation of the DNA-binding domain (96%) and of the C-terminal ligand-binding domain (58%). This suggests that ER would recognize and bind to similar EREs as ER but each receptor would have a distinct spectrum of ligands. The N-terminal AF-1, the hinge region and the F-domain (AF-2) are not conserved between the two receptors, suggesting that the different sets of proteins in the transcription complexes may interact with ER and ER and direct them to specific targets (Kuiper, Enmark et al. 1996; Weihua, Andersson et al. 2003). Different chromosomes encode the two receptors; ER has been mapped to 6q and ER to 14q (Enmark, Pelto-Huikko et al. 1997) and so, the expression of ER does not correlate with that of ER (Dotzlaw, Leygue et al. 1997).

Ligand-bound ER can modulate transcription by binding to the regulatory region of target genes directly through specific DNA sequences called oestrogen response elements or indirectly through other DNA binding transcription factors. The receptor interacts with coactivators or corepressors to enhance or repress transcription, respectively (Nilsson, Makela et al. 2001).

ER response elements

1)	Classical ERE: The classical oestrogen response element (ERE) is composed of two inverted hexanucleotide repeats, and ligand-bound ER binds to the ERE as a homodimer. When bound to oestradiol (E2), ER activates the expression of genes that have oestrogen responsive elements (ERE) in their promoter regions (Fig-2.4). Genes that have been shown to be oestrogen responsive include c-fos, c-jun, TPA (tissue plasminogen activator), bcl-2, TGF (transforming growth factor alpha) (Liu, Schwartz et al. 2000). Oestrogens stimulate the proliferation (via growth factors) and metastasis (via TPA and cathepsin D) of breast tumours.

2)	Non-classical response sites (Nilsson, Makela et al. 2001): The ERs also mediate gene transcription without directly binding to DNA. This occurs through protein-protein interactions with the SP1, AP1 (Fos/Jun activating protein-1) complex and NFB proteins. Genes regulated by binding ER indirectly include IGF-1 (insulin-like growth factor-1) and RAR-1 (retinoic acid receptor 1) gene. 
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Fig-2.4: Models of ER action at a classical ERE and an ER-dependent AP1 response element. (Black triangles represent the ligand bound to the ER. The AP1 proteins Jun and Fos are labelled J and F respectively.)


ER
	
ER mediates the effect of oestrogens, which include proliferation and differentiation in reproductive tissues and have been linked to the pathophysiology of breast cancer.

ER and oestradiol
ER is down-regulated in the presence of its ligand, oestradiol (E2) in normal mammary gland, through the ubiquitin proteasome pathway (Nawaz, Lonard et al. 1999). The half-life of ER is ~5 days in the absence of oestradiol, but only 3-4 hrs in the presence of oestradiol (Nirmala and Thampan 1995). In contrast, ER-positive breast cancer cells proliferate in response to oestradiol (Palmieri, Cheng et al. 2002).
ER and p53
The evidence looking at the interaction between ER and p53 has been contradictory. It has been shown that wild type p53 physically interacts with ER and represses oestrogen stimulated transcriptional activity thus down-regulating the expression of oestrogen-responsive genes (Yu, Yap et al. 1997). p53 mutants have no or reduced repression effect, depending upon the sites of mutation (Yu, Yap et al. 1997). This repression is due to p53 mediated inhibition of the binding of the liganded ER with ERE. p53 does not interfere with either ER dimerization or the interaction between ER and its co-activator SRC-1 (Liu, Schwartz et al. 1999). This evidence has been clinically supported by negative correlation between p53 and ER and Er-regulated proteins such as pS2.It has been shown recently that p53 upregulates ER expression by increasing the transcription of gene through a protein-protein interaction. (Angeloni, Martin et al. 2004). Interestingly a high percentage of breast tumours with p53 mutations are ER negative (Berns, Klijn et al. 1996). It has been postulated that the ability of p53 to control the expression of ER suggests that specific p53 mutations in breast tumours contribute not only to oncogenesis but also to the more aggressive phenotype associated with the loss of ER expression (Angeloni, Martin et al. 2004).

Earlier studies suggested that oestradiol induces functional inactivation of p53 by causing nuclear extrusion of p53. They correlated the intracellular redistribution of p53 to a reduced expression of p21 and to the presence of degradation products of p53 in the cytoplasm (Molinari, Bontempo et al. 2000). In contrast, recent studies suggest that oestradiol induces accumulation of active p53. p53 is rapidly degraded when MCF-7 cells are transferred to E2-depleted medium and E2 treatment significantly delays p53 degradation thus promoting its intranuclear accumulation (Okumura, Saji et al. 2002).

Prognostic value of ER
ER status is assessed semi-quantitatively on immunohistochemistry. There are predominantly two scoring systems that are widely used for this i.e. Allred score (Harvey, Clark et al. 1999) and Quickscore (Detre, Saclani Jotti et al. 1995). These scoring systems have superseded the previously described H-score (McClelland, Finlay et al. 1990; Andersen 1992), which is labour-intense and prone to inter-observer variation. The Quickscore involves assessment of a) intensity of staining by scanning the whole section at low power and b) proportion of brown staining nuclei. The intensity is scored from 0 to 3 corresponding to negative, weak, intermediate and strong staining. The proportion of stained nuclei are graded from 1 to 6 (1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 80-100%). The two factors are then multiplied to get the Quickscore (varies from 0-18). The Allred score involves assessing the a) intensity graded from 0-3 as above and b) proportion of brown staining nuclei graded from 0-5 (0  none; 1 = <1/100; 2 = 1/100-1/10; 3 = 1/10-1/3; 4 = 1/3-2/3; 5 = >2/3). The two factors are added to get the Allred score (ranges from 0-8). 

ER-positivity is defined as a Quickscore of 4 or more, lower score is considered as ER-negative. This differs from Allred scoring system, wherein a score of 3 or more is considered to be positive in order to include tumours with 1% -10% weakly staining cells for endocrine therapy.

Positive ER status (synonymous with ER) correlates with favourable prognostic features including a lower rate of cell proliferation and histologic evidence of tumour differentiation, and strongly predicts the response of primary and advanced disease to hormonal therapy (Millis 1980; Vollenweider-Zerargui, Barrelet et al. 1986; Chevallier, Heintzmann et al. 1988). But the later studies show that the difference in disease-free survival between ER-positive and ER-negative tumours is larger in the presence of adjuvant endocrine therapy compared with in its absence (Costa, Lange et al. 2002; Bardou, Arpino et al. 2003), thereby suggesting that the better prognostic index attributed to ER positivity is more likely to the therapy responsiveness of these tumours than their biologically less aggressive behaviour.

Nearly 80% of postmenopausal and 50-60% of premenopausal women express detectable levels of ER (1998; Osborne 1998). ER is required for oestrogen-stimulated growth and so most endocrine therapies for breast cancer are designed to either reduce circulating oestrogen levels (e.g. aromatase inhibitors in postmenopausal women), or to bind directly to the available ERs in a tumour rendering them non-functional (e.g. tamoxifen). Approximately 60% of patients with ER-positive tumours benefit from hormonal therapy compared to 5-10% of those with ER-negative tumours (Osborne 1998). The non-responsiveness of 30% of ER-positive tumours to endocrine therapy could be due to the existence of naturally occurring ER mRNA variants. The recurrent breast tumours may become ER-negative even if the primary was ER-positive and this loss of ER expression is associated with poor response to endocrine therapy (Kuukasjarvi, Kononen et al. 1996).
 SERM and SERD
SERMs (Selective oestrogen receptor modulators) are a class of oestrogen receptor (ER) ligands that, depending upon the cell and tissue in which they operate, can function as agonists or antagonists (McDonnell, Connor et al. 2002) and currently they form the first line of endocrine management of breast cancer. Tamoxifen functions as an anti-oestrogen in breast, but exhibits significant oestrogenic activity in the skeletal and cardiovascular systems, and in the uterus. So, tamoxifen is able to maintain bone density and reduced circulating cholesterol while being an effective breast cancer drug, but elevates the risk of uterine cancer. Another SERM, raloxifene, functions similar to tamoxifen in breast tumours (as an anti-oestrogen) and bones (agonist action) but functions as a pure antagonist in the uterus.

Molecular determinants for the tissue specificity of SERMs: Earlier studies (Brzozowski, Pike et al. 1997) indicated that agonists and antagonists demonstrate different binding modes at the same site within the core of ligand binding domain (LBD) and also, each ligand induces a distinct conformation in the transactivation domain of LBD thereby suggesting that the receptor conformation is a key regulator of receptor pharmacology.

It is now known that ER-mediated transcriptional activation is associated with the recruitment of coregulators (which in turn interact to allow ER to adopt different conformations), therefore the overall balance of the relative expression of coactivators and corepressors seems to be an important determinant of the tissue-specificity of SERMs. It has been shown that in breast where tamoxifen and raloxifene are both antagonists, both SERMs induce the recruitment of corepressors and not coactivators to ER target promoters (Shang and Brown 2002). In contrast, in the endometrium where tamoxifen acts as an agonist and raloxifene as an antagonist, tamoxifen recruits coactivators instead of corepressors to ER target genes that do not contain a classical ERE, such as c-Myc and IGF-1.

The potential problems with the use of partial agonists such as tamoxifen include the increased risk of endometrial cancer and the acquisition of tamoxoifen-resistance. In an attempt to overcome these problems with tamoxifen therapy, ‘pure’ antio-oestrogens have been developed such as Fulvestrant (ICI 182780). In contrast to SERMs, fulvestrant (Faslodex) binds, blocks and degrades the ER, leading to loss of ER and complete abrogation of ER function e.g. the expression of PgR is reduced after treatment with fulvestrant (Howell, Downey et al. 1996). Therefore, these drugs are grouped as selective oestrogen receptor downregulator (SERD). It has been shown that fulvestrant lacks any known agonist activity and inhibits the growth of tamoxifen resistant cell lines (Wakeling, Dukes et al. 1991). The clinical trials have also shown the effetiveness of this drug in patients failing on tamoxifen therapy (Howell, DeFriend et al. 1996). Recent clinical trials have shown that fulvestrant is effective and well tolerated in the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer (Jones and Pippen 2005; Robertson, Llombart-Cussac et al. 2009).



ER

ER was first identified in human testis (Mosselman, Polman et al. 1996) and its rat homolog was cloned and characterized from rat prostate (Kuiper, Enmark et al. 1996). ER binds to oestradiol with similar affinity to ER and activates the expression of reporter genes containing oestrogen response elements in an oestrogen-dependent manner, although less efficiently than ER (Mosselman, Polman et al. 1996; Kuiper, Carlsson et al. 1997). ER signals in ways opposite to that of ER when complexed to oestradiol from an AP1 site; with ER, 17-oestradiol activates transcription, whereas with ER, transcription is inhibited. Moreover, when antioestrogens like tamoxifen and raloxifene bind to ER, they are potent transcriptional activators at an AP1 site, acting as agonists rather than antagonists (Paech, Webb et al. 1997). Thus, the two receptors may have differential responses depending on ligand and response elements, thus suggesting their different roles in gene regulation.

ERs and mammary gland
ER is the predominant oestrogen receptor in the normal mammary gland and in the benign breast disease. Approximately 60-70% of epithelial cells express ER at all stages of breast development. There is very little ER in the normal mammary gland, but it is expressed abundantly in both invasive and in situ ductal carcinoma. ER is also expressed in breast cancer (Gustafsson and Warner 2000).
More than 90% of ER-bearing cells do not proliferate, and approximately 60% of proliferating cells do not contain ER or ER. This led to a suggestion that the presence of these receptors in epithelial cells is not a prerequisite for oestrogen-mediated proliferation. Two different types of responses to oestrogen in the breast have been postulated: (a) an indirect action of oestradiol in the mammary epithelium by inducing oestrogen receptor-containing stromal cells to produce growth factors that stimulate epithelial cells to divide and (b) a direct effect on ER-containing cells that occur at low oestrogen concentrations and result in induction of progesterone receptor (PR) (Saji, Jensen et al. 2000; Nilsson, Makela et al. 2001). This is in contrast to oestrogen action in breast cancer cells where ER-positive cells proliferate in response to oestradiol. Gustafsson et al reported that the major ER in breast stroma is ER and not ER as was previously thought. This suggested the possible role of ER in growth factor secretion in response to oestradiol and hence in cell proliferation in normal breast (Gustafsson and Warner 2000).
ERs and Breast Cancer 
Most breast tumours express ER, either alone or in combination with ER. In tumours coexpressing the two receptor subtypes, expression of ER is greater than that of ER and this coexpression marks a poor prognosis to the tumour. The ER-negative and ER-negative tumours are less common (23%) as compared to the ER-negative normal breast tissue (52%) (Speirs, Parkes et al. 1999). It has also been shown that in ER-positive tissues, the tumour shows higher ER: ER ratio compared to that of normal breast tissue (Leygue, Dotzlaw et al. 1998). This difference seems mainly due to an up-regulation of ER mRNA levels within the tumour tissues, but down-regulation of ER could also contribute to this altered ratio. This change of ER: ER gene expression during carcinogenesis suggests that both ER and ER specific pathways may have definitive roles in this process.
It has been observed that the presence of ER in breast cancer epithelium is associated with a decreased expression of the proliferation markers, Ki67 and cyclin A, whereas ER expression is associated with elevated levels of these markers (Jensen, Cheng et al. 2001). The cancers that are ER-negative and ER-positive have highest expression of Ki67 and cyclin A. These findings suggest that possibly ER and not ER, is related to proliferation in breast cancer. It has also been shown that ER is the only ER detected in the breast cancer stroma (Cunha, Young et al. 1997; Jensen, Cheng et al. 2001) and this may indicate its involvement in paracrine signalling mechanisms associated with tumour growth.


Cyclin D1 

The human CCND1/PRAD1 gene is located on chromosome 11q13 and spans approximately 15 kb including five exons (Motokura and Arnold 1993). The gene encodes a 295-amino acid protein with a molecular weight of 34kD (Motokura, Bloom et al. 1991) and is amplified in some 15% of breast cancers (Gillett, Fantl et al. 1994; Ormandy, Musgrove et al. 2003). However, cyclin D1 is overexpressed at the mRNA and protein level in over 50% of the breast cancers in the presence or absence of gene amplification (Buckley, Sweeney et al. 1993; Gillett, Fantl et al. 1994) and qualifies as one of the most commonly overexpressed proteins in breast cancer.

The stimulation of growth-arrested cells in response to various oncogenes such as ras, myc, E1A  (Hinds, Dowdy et al. 1994; Lovec, Grzeschiczek et al. 1994; Lovec, Sewing et al. 1994) and mitogenic growth factors such as members of EGF and IGF families result in the induction of the D-type cyclins (Musgrove, Hamilton et al. 1993). These cyclins link the extracellular signals to the cell cycle machinery (Sherr 1993) and of the three D-type cyclins, it is cyclin D1 that is predominantly associated with human tumorigenesis (Hosokawa and Arnold 1998).





Cyclin D1 and cell cycle regulation

Normal cell cycle
The p16-cyclinD1-cdk4-Rb pathway is central to the regulation of the G1-S phase transition in the cell cycle (Fig-2.5) and alteration or mutation of one of the components of this pathway is encountered in most human cancers, the most prominent being cyclin D1 (Motokura, Bloom et al. 1991; Jiang, Kahn et al. 1992; Schuuring, Verhoeven et al. 1992). G1 cyclins (cyclins D and E) control the progression through the restriction point during late-G1 phase when cells lose their dependency on mitogens and commit to DNA synthesis (Pardee 1989). 

Class D cyclins (D1, D2 and D3) bind to cdks 4 and 6 and phosphorylate various substrates including Rb protein (Matsushime, Quelle et al. 1994). The partial phosphorylation (inactivation) of Rb results in liberation of the transcription factors, predominantly the ones belonging to E2F family, which in turn activate various genes responsible for progression of S phase (Dyson 1998). The cyclin E1 gene is an E2F target and this results in induction of cyclin E1 protein in mid- to late-G1 phase, which in turn complexes with cdk2 and completes the phosphorylation of Rb (Kitagawa, Higashi et al. 1996; Sutherland and Musgrove 2004). This creates a positive feedback loop and contributes to the irreversibility of the G1/S transition (Sherr and Roberts 1999). p16INK4a protein is a negative regulator of the catalytic activity of cdk4 (Serrano, Hannon et al. 1993) and forms a key regulatory protein in cell cycle progression. In addition to Rb phosphorylation, the cyclin D-cdk4 complex sequesters CDKI (cdk inhibitors) including p27kip1 and p21cip1 (Sherr 1995), which in turn facilitates activation of cyclin E-cdk2 activation later in G1 phase.
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Fig-2.5: Regulation of the G1/S transition (Sherr and Roberts 1999)







Deviation from normal 

The oncogenic capacity of cyclin D1 has been established in various studies (Jiang, Kahn et al. 1993; Wang, Cardiff et al. 1994; Zhou, Jiang et al. 1995). It has been shown that induction of cyclin D1 in breast cancer cell lines shortens G1 and results in an increase in the number of cells progressing through G1 (Musgrove, Lee et al. 1994). This observation is supported by other studies demonstrating entry into S phase is prevented by inhibiting cyclin D1 expression (Baldin, Lukas et al. 1993; Quelle, Ashmun et al. 1993), thereby suggesting that cyclin D1 is essential for G1 progresssion. Moreover, cyclin D1, along with cyclin E, is rate-limiting for progress through G1 in various cell lines; cyclin D1 in early G1 and cyclin E in late G1 phase of the cell cycle (Musgrove, Hamilton et al. 1993; Quelle, Ashmun et al. 1993; Musgrove, Lee et al. 1994). 

Cyclin D1 plays a pivotal role in oestrogen-induced breast cancer with oestrogen action mediated through transcriptional activation of cyclin D1 and c-myc (Altucci, Addeo et al. 1996; Foster and Wimalasena 1996; Prall, Rogan et al. 1998). This evidence suggests a critical role for cyclin D1 in human breast cancer cell-cycle control. Given this role, overexpression of cyclin D1 may provide a growth advantage to the tumour cells and may also contribute towards resistance to endocrine therapy (Musgrove, Lee et al. 1994).


Cyclin D1 as a transcriptional regulator 

Cyclin D1 can regulate the growth of oestrogen-responsive tissues by activating the oestrogen receptor (ER) in a ligand-independent fashion i.e. in the absence of oestrogen (Zwijsen, Wientjens et al. 1997). Cyclin D1 binds to the hormone-binding domain of ER and promotes association between ER and one of its coactivators resulting in upregulation of ER-mediated transcription through a CDK-independent mechanism (Neuman, Ladha et al. 1997; Zwijsen, Wientjens et al. 1997). This oestrogen-independent ER-agonistic activity of cyclin D1 could underlie its oncogenic role in ER-positive breast cancer.
Transactivation by ER depends on binding of a leucine-rich motif present in the transactivation domain, AF-2 to the steroid receptor coactivators and this binding is ligand-regulated (Danielian, White et al. 1992; Voegel, Heine et al. 1996). The co-activators then recruit additional transcriptional factors, p300/CBP (p300/CREB-binding protein) and P/CAF (p300/CREB-binding protein-associated factor), which attach to ER and also interact with each other (Yao, Ku et al. 1996) to promote transcription by virtue of their inherent histone acetyltransferase activity (Bannister and Kouzarides 1996). It has been shown that cyclin D1 can interact with coactivators of the SRC-1 family and act as a bridging factor between ER and SRCs, thereby transactivating ER in the absence of the oestrogen ligand (Fig-2.6). A leucine-rich domain in the carboxy terminus of cyclin D1 is responsible for the interaction with SRC (Zwijsen, Buckle et al. 1998). Similarly, it has been demonstrated that cyclin D1 can interact with another transcriptional factor, P/CAF facilitating an association between P/CAF and ER; which in turn potentiates transcriptional activation by ER via histone acetytransferase activity (McMahon, Suthiphongchai et al. 1999).
More recent studies have shown that cyclin D1 can interact with variety of transcription factors such as androgen receptor, DMP1, C/EBP and histone acetylases and deacetylases independent of Cdks (Coqueret 2002; Sutherland and Musgrove 2004) suggesting a role as a transcriptional regulator in addition to the well-established Cdk-dependent role in cell cycle progression.


	

		



		a) No Ligand				b) Ligand (oestrogen) present


Fig-2.6
Model for cyclinD1-mediated ER transactivation (Zwijsen, Buckle et al. 1998). ER is unable to interact with SRC in the absence of its ligand because its leucine-rich domain is unavailable for interaction. Cyclin D1 is able to bind to ER in the absence of a ligand and also binds to SRC via leucine-rich domain, thereby acting as a bridge between ER and SRC resulting in transactivation of ER (a). Subsequent ligand (oestradiol, E2) binding of ER induces a conformational change in ER exposing the leucine-rich motif of ER, allowing higher affinity binding of SRCs to the liganded D1/ER complex (b). This model suggests a synergism between oestradiol and cyclin D1 for ER activation.

Cyclin D1 and oestrogen

The mitogenic effects of oestradiol (E2) are mediated by at least two E2 target genes, c-myc (Dubik and Shiu 1992) and CCND1 (Altucci, Addeo et al. 1996; Said, Conneely et al. 1997; Tong and Pollard 1999), each working independently (Prall, Rogan et al. 1998). Of the two regulatory genes, myc is activated earlier by E2 than CCND1 in the G1 phase (Prall, Sarcevic et al. 1997). These pathways converge at the activation of cyclin E-Cdk2 complexes (Fig-2.7). The active cyclin E-Cdk2 complexes are depleted of the cyclin dependent kinase (CDK) inhibitor p21 (waf1/cip1) being sequestered by cyclin D1 (Sherr 1995). Phosphorylation of pRB (retinoblastoma) follows in response to activation of cyclin E-Cdk2 and cyclin D- Cdk4 complexes, resulting in the release of transcription factors necessary for DNA synthesis and progression from G1 to S phase of the cell cycle (Foster and Wimalasena 1996; Doisneau-Sixou, Sergio et al. 2003).

E2 induces myc through the ER (oestrogen receptor) mediated signalling pathway by binding to the ERE (oestrogen response element) present in the promoter region of myc (Dubik and Shiu 1992). The cyclin D1 gene (CCND1) is not known to contain an ERE region in its promoter (Sabbah, Courilleau et al. 1999; Foster, Henley et al. 2001) and transcriptional activation is probably mediated through protein-protein interactions via a cAMP response element located close to the transcription start site. However, the role of additional non-ER pathway(s) have also been suggested in oestrogen-dependent tumour growth (Felty, Singh et al. 2005). The expression of early G1 (phase) genes, c-myc, c-fos, c-jun, and CCND1 (Cyclin D1) is regulated by reactive oxygen species (ROS) (Janssen, Matalon et al. 1997; Galli, Labato et al. 2003). Recently, it has been suggested that E2-induced mitochondrial reactive oxygen species (ROS) play a role in G1/S progression of oestrogen-stimulated breast cancer cells via activation of the transcription factor AP-1, which is known to be involved in the transcription of cyclin D1. Mitochondrial function blockade halted E2-induced cell cycle progression, accompanied by decreased expression of cyclins D and E, suggesting that in addition to ER signalling pathway, E2-induced mitochondrial ROS contribute to G1/S phase progression of oestrogen-stimulated breast cancer cells (Felty, Singh et al. 2005).
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						Fig-2.7
Mechanism of action of oestrogen in regulating cell cycle progression (adapted from (Doisneau-Sixou, Sergio et al. 2003).

Cyclin D1 in mammary gland development and carcinogenesis

Mammary gland development during pregnancy is impaired in cyclin D1 knockout mice (Fantl, Stamp et al. 1995; Sicinski, Donaher et al. 1995). However, development is normal if the inhibitory effect of Cdk inhibitors is removed by inducing p27kip1 deficiency in cyclin D1 null mice (Geng, Yu et al. 2001) or if cyclin D1 is replaced by cyclin E1, which is a downstream target of cyclin D1 (Geng, Whoriskey et al. 1999). Tissue specific expression of cyclin D1 in transgenic mice results in mammary hyperplasia and adenocarcinoma (Wang, Cardiff et al. 1994), though the carcinoma developed after a latent period suggesting the need of cooperation with other genetic events. Furthermore, cyclin D1-deficient mice are resistant to mammary carcinomas induced by c-neu/HER2 and ras oncogenes, but not those induced by c-myc and Wnt-1, suggesting that ras and c-neu signal via cyclin D1 to promote carcinogenesis (Yu, Geng et al. 2001). However, evidence from studies on human breast cancer provides conflicting information. For example, cyclin D1 overexpression correlates with ER-positive status, whereas breast tumours overexpressing Her-2 are predominantly ER-negative (Gullick 1990; Chodosh 2002). Although ADH (atypical ductal hypreplasia) is infrequently associated with cyclin D1 overexpression in human cohort studies (Weinstat-Saslow, Merino et al. 1995; Gillett, Lee et al. 1998), overexpression of cyclin D1 is seen in 50-80% cases of DCIS (Weinstat-Saslow, Merino et al. 1995; Simpson, Quan et al. 1997; Gillett, Lee et al. 1998) suggesting a role in human breast carcinogenesis. 

It was initially believed that a Cdk-dependent function of cyclin D1 resulted in progression through G1 phase and thus enhanced cellular proliferation lay behind its oncogenic potential. However, evidence from various clinical studies fails to support this hypothesis and therefore an alternative Cdk-independent function resulting in tumorigenesis has been suggested (Ewen and Lamb 2004). 
a)	Breast cancers overexpressing cyclin D1 do not show high levels of its downstream product, cyclin E, involved in the Cdk-dependent pathway involving Rb and E2F trancription factors (Fig-2.5) (Zukerberg, Yang et al. 1995; Nielsen, Loden et al. 1999).
b)	Tumours overexpressing cyclin D1 exhibit a relatively normal rate of proliferation, whereas cancers with overexpression of cyclin E or pRb defects show a high proliferation index (Jares, Rey et al. 1997; Nielsen, Loden et al. 1999).
c)	Cyclin D1 levels do not correlate with Ki-67 expression, a marker of cellular proliferation (Shoker, Jarvis et al. 2001). 
d)	Moreover, cyclin D1 is predominantly expressed in well-differentiated, low-grade, and slow growing breast cancers (Naidu, Wahab et al. 2002; Hwang, Han et al. 2003) suggesting the possibility that cyclin D1 may also be involved in cell differentiation and growth arrest (de Jong, van Diest et al. 1999) in addition to the well documented role in cell cycle progression.

Since cyclin D1 is overexpressed preferentially in ER-positive breast cancer, it has been suggested that modulation of transcription via its action on ER probably underlies the oncogenic activity of cyclin D1 in breast cancer (Zwijsen, Wientjens et al. 1997; Zwijsen, Buckle et al. 1998). This hypothesis is supported by the findings that show the direct interaction between cyclin D1 and ER, which in turn activates ER-regulated genes in the absence of oestrogen (Musgrove, Wakeling et al. 1989). 

Cyclin D1 and breast cancer

Cyclin D1 overexpression has been reported between 40-90% of cases of invasive breast cancer, while gene amplification is seen in about 5-20% of tumours (Gillett, Fantl et al. 1994; Weinstat-Saslow, Merino et al. 1995; Zukerberg, Yang et al. 1995; Michalides, Hageman et al. 1996). Though CCND1 amplification correlates well with the overexpression of the protein (Mrhalova, Kodet et al. 2002; Jirstrom, Stendahl et al. 2005), high expression of cyclin D1 is not always secondary to gene amplification (Buckley, Sweeney et al. 1993) implying that other mechanisms contribute to maintain cyclin D1 overexpression. Various factors that could contribute to protein overexpression in breast cancer include oestrogen (Musgrove, Hamilton et al. 1993; Altucci, Addeo et al. 1996) and p53 through p21Cip1 pathway (Chen, Bargonetti et al. 1995).

























Fig-2.8

Crosstalk between Rb and p53 pathway. The blue circles (cyclin D1 and mdm2) denote oncogenes while green squares (p53, p16 and Rb) represent tumour suppressor genes.

	



Correlation with tumour markers
a) ER and PgR
Cyclin D1 expression correlates strongly with ER and PgR levels in breast cancer (Zukerberg, Yang et al. 1995; Hui, Cornish et al. 1996; Michalides, Hageman et al. 1996; Barbareschi, Pelosio et al. 1997; Jares, Rey et al. 1997). However, a variable association has been reported by different studies between CCND1 amplification and ER status. While the majority report a positive association (Olsson, Borg et al. 1991; Peters, Fantl et al. 1995; Seshadri, Lee et al. 1996; Hui, Ball et al. 1998), some did not observe any link (Barbareschi, Pelosio et al. 1997).

b) p53 and p21
No association has been found between the expression of p53 and overexpression of its downstream effectors such as p21 and cyclin D1 in clinical studies (Barbareschi, Pelosio et al. 1997) though this contradicts the experimental data which suggests that cyclin D1 expression can be regulated by p53 through p21 (Chen, Bargonetti et al. 1995).

Evaluation of immunohistochemical staining

Cyclin D1 nuclear intensity on immunohistochemistry has been linked to the degree of amplification of CCND1 (Michalides, Hageman et al. 1996). Recently, a positive link has also been suggested between intensity of staining and resistance to tamoxifen treatment (Stendahl, Kronblad et al. 2004) suggesting that the intensity of staining and labelling index, should be recorded separately for cyclin D1.
Gene amplification and co-amplifications
CCND1 is amplified in 15-20% of breast cancer patients and this can be detected by the fluorescent in-situ hybridisation (FISH) technique using commercially available probes. This gene amplification may be reflected in the intensity of staining on immunohistochemistry (Michalides, Hageman et al. 1996; Jirstrom, Stendahl et al. 2005) (Fig-2.9).

The co-amplification of one or several oncogenes such as CCND1, HER2, mdm2, myc, EGFR occurs commonly in breast cancer, reported in upto 30% of CCND1- and up to 40% of HER2-amplified cancers (Al-Kuraya, Schraml et al. 2004). In patients with CCND1/HER2 co-amplification, the prognosis relates to HER2 amplification and the impact of CCND1 amplification appears minimal while with other co-amplifications such as HER2/myc, the effect is additive.

					












	

					Fig-2.9a



		
					Fig-2.9b
CCND1 amplification and cyclin D1 protein overexpression in the same patient. Cyclin D1 amplification (Fig-9a) demonstrated by FISH using CCND1/CEP11 probe (fluorescent microscopy, 100X) and this associates with the intensity of staining on immunohistochemistry (Fig-9b) using cyclin D1 monoclonal antibody (20X).



Prognostic value

Published evidence suggest that overexpression of cyclin D1 is a good prognostic factor in invasive breast cancer and associated with better patient outcome (overall survival and relapse-free survival) particularly for ER-positive patients (Gillett, Smith et al. 1996; Hwang, Han et al. 2003; Bilalovic, Vranic et al. 2005), although one study disagrees with this (Kenny, Hui et al. 1999). Conversely, gene amplification relates to early relapse and poor prognosis in ER-positive breast cancer (Michalides, Hageman et al. 1996; Seshadri, Lee et al. 1996; Bieche, Olivi et al. 2002). This controversy about the different prognostic value of the protein and the gene stems from the lack of studies assessing the two variables in the same set of patients. This conflict becomes more relevant in the light of available evidence suggesting that CCND1 amplification correlate well with the cyclin D1 overexpression (Mrhalova, Kodet et al. 2002). However a recent study has looked at the two variables in the same patient group (Jirstrom, Stendahl et al. 2005) and has suggested that both predict poor response to tamoxifen therapy in ER-positive breast cancer. The prognostic value of cyclin D1 overexpression with regards to recurrence and overall survival needs to be ascertained by further studies.
`
Response to antioestrogens

Antioestrogens inhibit breast cancer cell proliferation by blocking the entry of cells into S phase (Watts, Sweeney et al. 1994). This is mediated by an early decline in pRB phosphorylation effected by downregulation of Cdk activity due to downregulation of oestrogen-dependent cyclin D1 expression (Watts, Brady et al. 1995). Later, an increase in Cdk inhibitors p27Kip1 and p21Cip1 maintain repression of Cdk activity (Wilcken, Prall et al. 1997; Hui, Finney et al. 2002).
The molecular action of cyclin D1 could be mediated either through its partial ER-agonist effect (Zwijsen, Wientjens et al. 1997) or via its ability to sequester Cdk-inhibitors during G1/S transition resulting in propogation of cell proliferation (Sherr 1995; Zhou, Hopp et al. 2001). In addition, both cyclin D1 over-expression and gene amplification have recently been shown to predict poor response to anti-oestrogen therapy in ER-positive breast cancer patients (Stendahl, Kronblad et al. 2004; Jirstrom, Stendahl et al. 2005). Studies of breast cancer cell lines suggested that the ectopic overexpression of cyclin D1 reverses the anti-proliferative effect of antioestrogens (Hui, Finney et al. 2002), though some contradictory results have also been reported (Pacilio, Germano et al. 1998). However, clinical studies of tamoxifen as an adjuvant therapy in ER-positive breast cancer show a higher response and better survival rate in cancers with cyclin D1 low/moderate expression than those with high expression of cyclin D1 (Stendahl, Kronblad et al. 2004; Jirstrom, Stendahl et al. 2005). This adverse effect was obtained within 2 years of initiating adjuvant tamoxifen treatment and may be an underlying reason for the failure of anti-oestrogen therapy in some tumours despite them being ER-positive. CCND1 amplification is a stronger predictor of tamoxifen response than protein expression, though the latter has a significant correlation (Jirstrom, Stendahl et al. 2005). One small study did not observe a relationship between cyclin D1 expression and response of bony metastases to tamoxifen therapy(Han, Park et al. 2003). This implies that evaluation of expression of cyclin D1 could assist in determining optimal adjuvant therapy in addition to it being a prognostic variable in ER-positive breast cancer. 
Currently there is no evidence available to suggest if cyclin D1 overexpression has any association with response to aromatase inhibitors.

Response to radiotherapy

Experimental evidence suggests that cyclin D1-overexpression in breast cancer cell lines increases sensitivity to ionizing radiation (Coco Martin, Balkenende et al. 1999). Enhanced apoptotic response was observed after MCF-7 cells with cyclin D1 overexpression were exposed to radiation, thought to be due to sustained high levels of p53 and p21 after their initial induction by the radiation, the mechanism of which is unclear.

Therapeutic value

A recent experimental study has reported modulation of MCF-7 cell line growth rate by regulated overexpression or suppression of endogenous cyclin D1 or CDK4 levels (Grillo, Bott et al. 2005), suggesting cyclin D1-CDK4 may be a target in cancer therapeutics. Together, the knowledge that the p16INK4a-cyclin D1-CDK4-Rb axis is commonly altered pathway in human cancers, the increasing evidence of role of cyclin D1 in oncogenesis (thus qualifying as a proto-oncogene) and the recent discovery of CDK4 inhibitors (Soni, O'Reilly et al. 2001; Engler, Furness et al. 2003), CDK4 dependent Rb phosphorylation could potentially be a future target of anticancer drugs.
 

Summary

CCND1 is an oestrogen-responsive gene and carries an oncogenic potential by actions influencing cell cycle regulation at the G1/S phase transition and transcriptional regulation. Its product, cyclin D1 is overexpressed in more than half of invasive breast cancers. Recent evidence suggests that cyclin D1 interferes with the effect of tamoxifen and ER-positive breast cancers with cyclin D1 overexpression could potentially account for treatment failure while on tamoxifen therapy. The current data suggest that cyclin D1 merits further investigations as a marker of disease response and prognosis and offers future therapeutic opportunities.











DNA Replication Licensing Proteins (mcm2 and geminin)

Replication of the human genome is a highly coordinated process that ensures accurate and efficient transmission of the genetic information and DNA replicates only once in a single cell cycle (Blow and Laskey 1986; Blow and Laskey 1988). To ensure this, cells have developed control mechanisms that prevent partial or re-replication. In the case of errors in replication, genetic alteration could result in cell death or malignant transformation. The control mechanisms ensure the temporal order of the S-phase and M-phase (Blow 1993; Sherr 1994).
Cyclin dependent kinases (Cdks) are the master regulators of the cell cycle. Cdk2, 4 and 6 function at the onset of the S phase while Cdk1 (Cdc2) is required for the initiation of M-phase (Nurse 1994; Sherr 1994). DNA replication is regulated by the sequential action of Cdks, coupled to S-phase cyclins and to mitotic cyclins during the cell cycle. When Cdk activity drops at the end of the M-phase, the cells become reset for replication. The increase in Cdk activity at G1/S triggers initiation and the accumulation of mitotic Cdk prevents re-replication in G2 cells (Nasmyth 1996). 

How do Cdks achieve this global regulation?

What is DNA replication licensing?

When chromatin becomes competent for replication, it is referred to as being ‘licensed’. The licensing depends upon the prior assembly at the replication origins of a pre-replication complex (pre-RC) composed of origin recognition complex (ORC), Cdc6/18, Cdt1 and mcm proteins. All these proteins are present in the nucleus and their association with the chromatin brings about the activation (Young, Suzuki et al. 1997; Walter, Sun et al. 1998). The formation of replication competent chromatin involves the sequential binding of these proteins onto the DNA (Coleman, Carpenter et al. 1996; Rowles, Tada et al. 1999; Nishitani, Lygerou et al. 2000; Oehlmann, Score et al. 2004).

Replication licensing factor (RLF/ pre-RC) licenses replication origins during late mitosis or early G1 by putting them into an initiation-competent state (Blow and Laskey 1988; Chong, Mahbubani et al. 1995). The licensing factors are inactive during mitosis and become activated at the end of M-phase/ early G1, which corresponds to low Cdk activity (Blow 1993; Mahbubani, Chong et al. 1997). When the cells are committed to a new cell cycle i.e. at the G1-S phase transition, a second signal (initiation signal) i.e. Cdks induce licensed origins to initiate DNA replication (Blow and Nurse 1990; Fang and Newport 1991; Chevalier, Tassan et al. 1995; Jackson, Chevalier et al. 1995) and in doing so removes or inactivates the license complex (Thommes, Kubota et al. 1997). The dissolution of pre-RC is brought about, first by dissociation of Cdc6 (Rowles, Tada et al. 1999) and then by the gradual release of mcm proteins as S-phase proceeds (Krude, Musahl et al. 1996). Thus, during S-M phase, licensings are inactive thereby preventing re-licensing and this phase corresponds to high CDK activity. Therefore, the licensing signal and the replication initiation signal must act sequentially, but never simultaneously in order to result in precise duplication of DNA (Chong, Thommes et al. 1996).


Factors for licensing (Fig-10)

Origin Recognition Complex (ORC) complex
Origin Recognition Complex (ORC) constitutes the initiator proteins that bind to replication origins and is composed of six subunits, Orc1p-Orc6p (Bell and Stillman 1992; Diffley and Cocker 1992). ORC is essential for licensing and the binding of mcm proteins to chromatin is dependent on the presence of ORC; however, the binding of ORC to chromatin does not require mcms (Romanowski and Madine 1996). ORC remains chromatin-bound throughout the S phase (and also G2 and early M phases) (Diffley and Cocker 1992; Romanowski and Madine 1996; Rowles, Chong et al. 1996) unlike mcm proteins which are removed from DNA as it replicates (Chong, Mahbubani et al. 1995; Madine, Khoo et al. 1995; Kubota, Mimura et al. 1997).

Cdc6 (cell division cycle)
The Cdc6 protein is essential for the replication licensing but not for elongation of DNA (Coleman, Carpenter et al. 1996; Donovan, Harwood et al. 1997). ORC first binds to DNA and then recruits Cdc6 and this in turn recruits the mcm2-7 hexamer to form pre-RC at each replication origin (Tanaka, Knapp et al. 1997). It has been suggested that Cdc6 modifies the interaction of ORC with chromatin (Mizushima, Takahashi et al. 2000). Once licensing has occurred, ORC and Cdc6 are no longer required for the continued association of mcm2-7 with DNA (Donovan, Harwood et al. 1997; Rowles, Tada et al. 1999). Cdc6 is displaced from chromatin soon after mcm2-7 starts loading and this progresses during the S phase (Rowles, Tada et al. 1999; Oehlmann, Score et al. 2004). This translocation of Cdc6 to the cytoplasm is dependent upon CDK2 mediated phosphorylation of Cdc6 (Fujita, Yamada et al. 1999; Petersen, Lukas et al. 1999).
Cdc6 (and mcm) is expressed selectively in proliferating cells but not in quiescent mammalian cells. The transcription of Cdc6 (and mcm) during the transition from G0 to G1 phase is regulated by E2F proteins (Yan, DeGregori et al. 1998; Ohtani, Iwanaga et al. 1999).
The formation of pre-RC is blocked throughout S-M phase in vivo by Cdks along with cyclin B by inhibitory phosphorylation of Cdc6 (Dahmann, Diffley et al. 1995; Piatti, Bohm et al. 1996; Lopez-Girona, Mondesert et al. 1998). So Cdc6 is the key target of Cdk-cyclins in order to limit the DNA replication to once per cycle (Lopez-Girona, Mondesert et al. 1998).

Cdt1 (Cdc 10 dependent transcript 1)
Cdt1 was first identified in S. pombe as a gene induced by the CDK-dependent transcription factor Cdc10 (Hofmann and Beach 1994). Cdt1 cooperates with Cdc6 to promote DNA replication and is necessary for DNA licensing (Hofmann and Beach 1994; Maiorano, Moreau et al. 2000; Nishitani, Lygerou et al. 2000). Both Cdc6 and Cdt1 are required to load mcm hexamer on to the chromatin. Cdt1 binds to ORC independent of Cdc6 and is tightly regulated so that its protein accumulates only in G1, when licensing is legitimate, and is destabilised from chromatin upon initiation of DNA synthesis (Maiorano, Lemaitre et al. 2000; Nishitani, Lygerou et al. 2000). These observations suggest that Cdt1, similar to Cdc6 is required for the establishment but not the maintenance of the pre-RC. The regulation of Cdt1 is mediated by targeted proteolysis from S phase to mitosis, rather than by transcriptional controls (Nishitani, Taraviras et al. 2001).
Cdt1 is inhibited by geminin, an inhibitor of DNA licensing which binds to Cdt1 and inhibits its mcm loading function (Wohlschlegel, Dwyer et al. 2000; Tada, Li et al. 2001). Cdt1 is negatively regulated by geminin and during the cell cycle, geminin accumulates in S phase and G2, when Cdt1 levels are low, while Cdt1 accumulates in G1, when geminin is undetectable (McGarry and Kirschner 1998; Wohlschlegel, Dwyer et al. 2000; Nishitani, Taraviras et al. 2001).
Cdt1 (along with Cdc6, mcm and geminin) is down regulated in G0 phase (quiescent cells) and re-accumulates when cells are induced to re-enter the cell cycle (Xouri, Lygerou et al. 2004). This is transcriptionally regulated by E2F in contrast to post-transcriptional regulation during the cell cycle (Yan, DeGregori et al. 1998; Ohtani, Iwanaga et al. 1999; Xouri, Lygerou et al. 2004). Cdt1 (and geminin) is consistently over-expressed in cancer cell lines (Arentson, Faloon et al. 2002; Wohlschlegel, Kutok et al. 2002; Xouri, Lygerou et al. 2004). A potentially oncogenic role has also been suggested for Cdt1 (Arentson, Faloon et al. 2002) as overexpression of Cdt1 promotes rereplication (Vaziri, Saxena et al. 2003).

MCM complex

mcm (mini-chromosome maintenance) genes were first isolated in yeast (S. cervisiae) mutants that were unable to initiate replication at specific replication origins (Maine, Sinha et al. 1984). Sequence comparison of the genes suggests that they fall into six related groups termed mcm2-7(Chong, Thommes et al. 1996; Tye 1999). These six proteins mcm2-7 form a hexameric complex with a molecular weight between 300 and 550 kDa (Thommes, Kubota et al. 1997; Tye 1999). mcm proteins are present in abundance in both the cytoplasm and the nucleus at all stages of the cell cycle. However only a small proportion, about 5%-10% associates (constituting the active form) with chromatin from early G1 phase to the beginning of S phase, when replication initiation begins (Fig-10) (Blow and Laskey 1988; Young and Tye 1997). 
mcm complex is a key component of the pre-replication complex that assembles at replication origins during early G1 phase and this requires synchronous binding of all the six mcm2-7 proteins to the chromatin before the onset of S-phase (Thommes, Kubota et al. 1997; Tye 1999). The six mcm proteins can interact with one another to form multiple complexes; however, only the hexamer possesses licensing activity (Maiorano, Lemaitre et al. 2000; Prokhorova and Blow 2000).  In addition to licensing, mcm proteins are also essential for DNA elongation. They possess helicase activity (Ishimi 1997) and all the six components are necessary for the elongation of replication forks (Labib, Tercero et al. 2000). It has been shown that mcm proteins associate with origin sequences in pre-replication complexes, but move with replication forks after initiation, as expected for DNA helicase (Aparicio, Weinstein et al. 1997). It has been suggested that the structural change in the mcm2-7 complex switches on the helicase activity (Labib, Tercero et al. 2000). In addition, some mcm proteins interact with transcription factors and thereby their role in transcriptional regulation has also been suggested (Yankulov, Todorov et al. 1999; DaFonseca, Shu et al. 2001).
The mcm complex is gradually displaced from the chromatin as the replication forks progress during the S phase such that it is bound only to the unreplicated chromatin (Krude, Musahl et al. 1996). This coincides with cell-cycle dependent phosphorylation of mcm4 by cdc2/cyclinB kinase (Kimura, Nozaki et al. 1994; Coue, Kearsey et al. 1996; Hendrickson, Madine et al. 1996). This phosphorylation changes the affinity of the mcm2-7 for the chromatin and thereby promotes the release of the whole mcm complex from the chromatin (Hendrickson, Madine et al. 1996). This process starts in S phase and peaks at the G2/M transition of the cell cycle coinciding with the activity of the cdc2 protein kinase. This also leads to formation of an inactive, hyperphosphorylated, non-chromatin-bound mcm proteins from late S phase through mitosis, thus preventing illegitimate DNA replication during this period of cell cycle (Coue, Kearsey et al. 1996; Hendrickson, Madine et al. 1996).
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Fig-2.10

DNA replication licensing control during the cell cycle.


 Regulation of replication licensing 

Replication licensing is regulated such that re-licensing is prevented until the cells have passed through mitosis. This ensures single replication per cell cycle and maintains genomic integrity. The various regulatory factors that help in achieving this are:
1.	Cdks: High Cdk ctivity during S to M phase inactivates several components of preRC by phosphorylation and nuclear exclusion (Nguyen, Co et al. 2001).
2.	Degradation of Cdc6
3.	Ubiquitination of Orc1 during the S phase (Li and DePamphilis 2002)
4.	Geminin: Geminin interacts with Cdt1 protein and prevents the loading of mcm2-7 complex on the chromatin thus inhibiting DNA replication (McGarry and Kirschner 1998; Wohlschlegel, Dwyer et al. 2000; Tada, Li et al. 2001).

Initiation of DNA replication

To initiate DNA replication, the pre-RC needs to be activated in late G1 and at the G1-S phase transition by S-phase specific kinases that include CDK (Clb-Cdc28) and Cdc7-Dbf4 protein kinase called DDK (Dbf4 dependent kinase) (Stillman 1996; Owens, Detweiler et al. 1997). Cdc45 is a critical component for the conversion of the pre-RC to the pre-initiation complex (pre-IC) (Owens, Detweiler et al. 1997; Zou and Stillman 1998).

Cdc45p
Cdc45p is a protein essential for initiation of DNA replication that starts to associate with chromatin in late G1, but mainly during the S phase of the cell cycle (Zou and Stillman 1998; Takisawa, Mimura et al. 2000). The binding of Cdc45 to chromatin depends upon Clb-Cdc28 kinase activity as well as on functional Cdc6 and mcm2, which suggests that Cdc45 associates with the pre-RC after activation of S-phase kinases and therefore, is not a component of pre-RC (Zou and Stillman 1998). Cdc45 is essential for the sequential loading of replication protein A (RPA), DNA polymerase alpha and proliferating cell nuclear antigen (PCNA) onto chromatin (Mimura, Masuda et al. 2000; Zou and Stillman 2000). 
It has been shown that both S-CDKs and Cdc7-Dbf4 are required for the efficient binding of Cdc45 to replication origins (Zou and Stillman 2000). This in turn leads to formation of a complex containing mcm, Cdc45p and RPA at each origin (pre-initiation complex). This complex is involved in origin unwinding (Mimura, Masuda et al. 2000; Takisawa, Mimura et al. 2000; Zou and Stillman 2000) and recruiting other proteins (DNA polymerase alpha and epsilon) to assemble replication elongation complexes (Zou and Stillman 2000).

Licensing machinery in out-of cycle cells

Cells in G0 phase
All the essential replication factors ORC, Cdc6 and mcm are present throughout the human proliferative cell cycle (Musahl, Holthoff et al. 1998; Stoeber, Tlsty et al. 2001). ORC remains chromatin bound throughout the cell cycle and apparently maintains the same state in G0 (quiescent) cells (Musahl, Holthoff et al. 1998; Stoeber, Tlsty et al. 2001). However the functional state of this chromatin-bound ORC with regards to DNA replication is questionable (Madine, Swietlik et al. 2000). The persistence of ORC in quiescent states is attributed to its role in maintaining the silenced state of the cell such as transcriptional silencing and this function is independent of DNA replication (Fox, Loo et al. 1995). 
When the cells enter into G0 from G1 phase, mcm proteins (and Cdc6) are first displaced from the chromatin and are then downregulated as a gradual response to prolonged quiescence (Musahl, Holthoff et al. 1998; Madine, Swietlik et al. 2000; Stoeber, Tlsty et al. 2001). When quiescent cells are stimulated to re-enter the proliferative cell cycle, transcript and protein levels of Cdc6 and mcms increase during progression through G1, peaking on S phase entry, which in turn is regulated by E2F proteins (Tsuruga, Yabuta et al. 1997; Yan, DeGregori et al. 1998). 

Differentiated and senescent cells
The process of differentiation is associated with loss of proliferative capacity and this is associated with downregulation of Cdc6 and mcm constituents of the replication initiation pathway (Stoeber, Tlsty et al. 2001).
Senescent cells represent the somatic cells at the end of their replicative lifespan and irreversibly arrest proliferation with a G1 phase DNA (Campisi 1996). Senescence is associated with a decrease in the proportion of mcm-positive cells, which correlates well with the definition of senescence i.e. gradual decline in proliferating cells (Stoeber, Tlsty et al. 2001). The senescent cells show downregulation of Cdc6 and mcm but not ORC (Stoeber, Tlsty et al. 2001) and this has been linked to deficiency in the activity of E2F (Dimri, Hara et al. 1994). The protein levels of the cyclin-dependent kinase inhibitor (CDKI) p21/CIP1 are also upregulated in senescent cells(Stoeber, Tlsty et al. 2001).

Conclusions
a) The repression of mcm and Cdc6 proteins of the replication licensing pathway results in loss of replication competence and appears to be an important growth regulatory mechanism contributing to the suppression of proliferation in quiescent, differentiated and senescent cells (Stoeber, Tlsty et al. 2001; Blow and Hodgson 2002).
b) Cdc6 and mcm proteins are present in all phases of the proliferative cell cycle, but are downregulated in quiescent, differentiated and replicative senescent ‘out-of-cycle’ states, therefore they can be classified as proliferation markers (Stoeber, Tlsty et al. 2001).

mcm in breast epithelial cells

Breast tissue is characterised by low proliferative activity; the proliferative indices for lobular cells in pre-menopausal breast vary from 0% to 11.5%, the higher values corresponding to the secretory phase of the menstrual cycle (Potten, Watson et al. 1988). However a high proportion of lobular cells express mcm (40-60%) (Blow and Hodgson 2002) compared with conventional proliferation markers such as Ki67 (4-10%) (Potten, Watson et al. 1988). This suggests the existence of a population of cells in the lobules of adult pre-menopausal breast that are licensed to replicate and thus have proliferative potential but are rarely synthesizing DNA (in-cycle-arrest) (Stoeber, Tlsty et al. 2001).

Mcm as a biomarker

Mcm could be regarded as a biomarker of growth as it allows detection of cells with proliferative potential, in addition to actively proliferating cells (Stoeber, Tlsty et al. 2001). It was observed in various studies involving different cancers e.g. breast cancer (Stoeber, Tlsty et al. 2001), malignancies of colon, skin and bladder (Freeman, Morris et al. 1999), cervical dysplasia (Williams, Romanowski et al. 1998) that in comparison to routinely used proliferation markers such as Ki67, PCNA, mitotic index or thymidine labelling, antibodies against mcm consistently label a higher proportion of tumour/premalignant cells. This indicates that the neoplastic dynamic cell population contains both cells with proliferative potential and actively proliferating cells (Stoeber, Tlsty et al. 2001) and working on this rationale, mcm could potentially be a sensitive proliferation marker. Moreover, identification in tumours of actively proliferating, replication-licensed and non-proliferating cells without a license may be of importance in predicting prognosis. This multi-parameter analysis of tumour cell population using a combination of conventional proliferation markers and biomarkers of replication licensing may allow more accurate prediction of the efficacy of anti-tumour drugs that target DNA replication (Stoeber, Tlsty et al. 2001).



Geminin

Geminin is a 25-kDa nuclear protein that was discovered by screening cDNA libraries for novel proteins that were destroyed during mitosis (McGarry and Kirschner 1998). Geminin interacts with Cdt1 during S-G2-M phase and inhibits loading of the mcm complex onto the chromatin, thus preventing DNA overreplication and maintains genomic integrity by limiting DNA replication to once per cell-cycle (Wohlschlegel, Dwyer et al. 2000; Tada, Li et al. 2001).  Geminin is essential in human cells to prevent re-replication, and loss of geminin is sufficient to induce genomic instability; thus suggesting that geminin is a putative tumor suppressor gene (Melixetian, Ballabeni et al. 2004; Zhu, Chen et al. 2004).

Structure and function of geminin

The geminin molecule is a tetramer formed by two dimers, the monomers associate through the coiled-coil domain to form the dimers and this dimerization is essential for activity (Okorokov, Orlova et al. 2004). The N-terminus of the dimer interacts with Cdt1 and the C-terminus prevents access of the mcm complex to Cdt1 through steric hindrance, thus inhibiting initiation of replication (Lee, Hong et al. 2004). Geminin contains a nuclear localization signal that is also required for its destruction during mitosis. Nondegradable mutants of geminin interfere with DNA replication in succeeding cell cycles (Lee, Hong et al. 2004).
Geminin is absent in G1 phase cells when the pre-RCs are formed, expressed in S phase where it inhibits re-licensing of DNA thus preventing re-replication, persists through G2 and M phases and is degraded before the next G1 phase (McGarry and Kirschner 1998). Geminin is degraded by ubiquitin-dependent proteolysis during mitosis at the metaphase-anaphase transition and this is mediated by anaphase-promoting complex (APC) that ubiquitinates its N-terminal destruction box sequence (McGarry and Kirschner 1998). Studies have shown that overexpression of mutant (non-degradable) geminin stabilizes the protein in G1 and induces G1 arrest, probably by preventing pre-RC formation (Shreeram, Sparks et al. 2002; Wohlschlegel, Kutok et al. 2002). Depletion of Cdt1 also leads to cell-cycle block while overexpression of Cdt1 can overcome the inhibition by geminin resulting in rereplication in mammalian cells (Saxena and Dutta 2003). In other words, geminin-Cdt1 balance is critical for genomic integrity (Saxena and Dutta 2005).
In some organisms, there are additional checkpoints such as p53 in addition to geminin that prevent rereplication (Quinn, Herr et al. 2001). However in humans, inhibition of geminin expression is sufficient to induce re-replication in the presence of functional p53 (Melixetian, Ballabeni et al. 2004; Zhu, Chen et al. 2004). Geminin may suppress the activity of p53 by its inhibiting action on p14ARF, which in turn prevents the p53 degradation by mdm2 (Agrawal, Yang et al. 2006).


Expression of geminin and its clinical relevance

Geminin is expressed from S to M phase (Fig-2.11) and the number of geminin-expressing cells is directly proportional to the cell proliferation index as measured by Ki-67 expression (Wohlschlegel, Kutok et al. 2002). In contrast to mcm proteins that identify all non-quiescent cells, geminin identifies the sub-fraction that has entered S phase, but not exited mitosis, thereby reflecting upon the rate of cell-cycle progression (Gonzalez, Tachibana et al. 2004). It has been shown to be overexpressed in various cancers such as breast, rectal and colon (Montanari, Boninsegna et al. 2005).











Fig-2.11
Diagrammatic representation of expression of replication licensing proteins (mcm2-7), Ki67 and licensing repressor (geminin) during the cell cycle.


Geminin and breast cancer

The information with regards to prognostic value of geminin is rather limited. There is only one study reported so far in the literature, which states that geminin overexpression (labelling index, LI >6%) predicts adverse clinical outcome in terms of overall survival and time to distant metastasis in breast cancer (Gonzalez, Tachibana et al. 2004).

p53


The p53 gene is located on the short arm of the chromosome 17 (17p13.1) and comprises of 11 exons interrupted by 10 introns (Chang, Syrjanen et al. 1993). This gene encodes a 393-amino-acid, 53 kDa nuclear phosphoprotein involved in the regulation of cell proliferation. Despite its original misclassification as an oncogene, it became apparent that p53 is an essential mediator in most types of human cancers. p53 mutations are estimated to occur in approximately 50% of all cancers (Levine, Momand et al. 1991; Chang, Syrjanen et al. 1993) making this protein the most commonly mutated in human cancers. p53 function is not absolute for normal growth and function; however, mice lacking p53 show a high incidence of tumour development. p53 mutations may also be inherited in families with a predisposition to multiple cancers, as in the Li-Fraumeni Syndrome (LFS) (Malkin, Li et al. 1990).

p53 protein has a short life of about 20 min and is virtually undetectable in normal cells (Oren, Maltzman et al. 1981; Gannon, Greaves et al. 1990; Reihsaus, Kohler et al. 1990) whereas mutant forms have half-lives of several hours (Finlay, Hinds et al. 1988). p53 accumulation in breast cancer as detected by immunohistochemical assay correlates with p53 gene mutation and also shows a significant association with poor prognosis (Thor, Moore et al. 1992). p53 protein is stabilized in response to different checkpoints activated by DNA damage, hypoxia, viral infection, or oncogene activation resulting in diverse biological effects, such as cell cycle arrest, apoptosis, senescence, differentiation, and antiangiogenesis in order to prevent the proliferation of genetically unstable cells (Giaccia and Kastan 1998; Lohrum and Vousden 1999; Jin and Levine 2001). The ability of p53 to induce apoptosis is thought to be central to its tumour-suppressor activity (Bates and Vousden 1999). At the same time, p53 must be kept inactive in unstressed cells, as inappropriate activation can induce cell cycle arrest, premature senescence or death (Bottger, Bottger et al. 1997; Mendrysa, McElwee et al. 2003).

Structure of p53 

The human p53 protein contains 393 amino acids and contains three recognised domains with specific functions (Fig-2.12). The N-terminus (residues 1-63) constitute the transactivation domain which positively regulate gene expression (Unger, Nau et al. 1992; Candau, Scolnick et al. 1997). It contains regions forming protein-protein interactions with regulatory proteins such as mdm2 (residues 19-26 of p53), which triggers ubiquination and degradation of p53 (Momand, Zambetti et al. 1992), and p300/CBP that is responsible for acetylation of residues in the C-terminal part of p53 (Grossman 2001). The central sequence-specific DNA-binding domain (residues 102-292) (Pavletich, Chambers et al. 1993; Wang, Reed et al. 1993) is the most important independent domain. The C-terminal consists of tetramerization domain (residues 324-355) required for oligomerization of the protein (Wang, Reed et al. 1993), and C-terminal, inhibitory domain (residues 363-393) that contains the acetylation and phosphorylation sites and regulates the DNA binding activity of p53 (Hupp, Meek et al. 1992; Prives and Manley 2001). More than 90% of the missense mutations in p53 affect the sequence-specific domain (Pavletich, Chambers et al. 1993).




			
Fig-2.12: Structure of p53


p53 activation

The activation of p53 in response to genotoxic stresses involves first stabilization and then activation in order to stimulate the downstream events to bring about the cellular response. 

Phosphorylation-acetylation cascade
In response to DNA damage, p53 is phosphorylated at the N-terminus, while the C-terminus contains phosphorylated, acetylated and sumoylated residues (Appella and Anderson 2001). At least seven serine (Ser6, 9, 15, 20, 33, 37, 46) and two threonine (Thr18, 81) residues at the N-terminus are known to undergo phosphorylation in response to various stimuli. At the C-terminus, Ser315 and Ser392 are phosphorylated, Lys320, 373, and 382 are acetylated, and Lys386 is sumoylated in response to DNA damage, while Ser 376 and 378 are known to be constitutively phosphorylated in unstressed cells (Appella and Anderson 2001). It is thought that different types of DNA damage activate different enzyme systems, which in turn modify p53 at different amino-acid residues. These varying post-translational modifications in p53 transmit the nature of cellular stress, which in turn translates to switching on the corrective pathway that is appropriate for the causative stress signal (Giaccia and Kastan 1998; Colman, Afshari et al. 2000). For example, gamma-radiation activates the ATM kinase (Ataxia Telengiectasia Mutant) and the Chk-2 kinase (checkpoint kinase), which phosphorylate Ser15 and Ser20 respectively, while UV-radiation activates ATR (Ataxia Telengiectasia Related kinase), Chk-1 kinase and casein kinase which phosphorylate ser15 and 37, Ser20 and Thr 18 respectively (Appella and Anderson 2001). Until recently, it was thought that phosphorylation of N-teminal residues such as Ser15 inhibits the interaction of p53 with mdm2 and therefore, essential for stabilizing of p53 (Shieh, Ikeda et al. 1997; Sakaguchi, Herrera et al. 1998). 

p53 phosphorylation and function

Stress-induced p53 activation involves post-translational modification of p53 on multiple sites by phosphorylation, acetylation, and sumoylation (Vogelstein, Lane et al. 2000; Brooks and Gu 2003). The phosphorylation of p53 has been studied very extensively and has been proposed to play a critical role in the stabilization and activation of the tumour suppressor. Multiple serine residues (6,9,15,20,33,37,46,315,371,392) and three threonine residues (18,55,81) have been reported to undergo phosphorylation in response to diverse stresses (Jimenez, Khan et al. 1999). Residues from the N-terminal mdm2-binding domain of p53 (Ser20 and Thr18) have been shown to play a critical role in the interaction between the two proteins and their stress-induced phosphorylation decreases substantially the affinity between p53 and mdm2 (Craig, Burch et al. 1999; Schon, Friedler et al. 2002), thus stabilizing p53. 

However, evidence is now accumulating which suggest that phosphorylation of p53 is dispensable for transcriptional activation and apoptosis. The studies suggest that the phosphorylation status of p53 does not affect the biological function of p53 and the key lies in separating mdm2 from p53 in order to stabilize/activate the same (Ashcroft, Kubbutat et al. 1999; Jackson, Agarwal et al. 2004; Thompson, Tovar et al. 2004). The phosphorylation at the N-terminal mdm2-binding site could achieve this activation, but question arises as to how do mutant p53 proteins that cannot be phosphorylated achieve activation as seen in previous studies (Ashcroft, Kubbutat et al. 1999). The answer to this is suggested by a recent study that shows damage-induced phosphorylation of mdm2 itself, which triggers the preferential degradation of mdm2 by auto-ubiquitination (Stommel and Wahl 2004; Stommel and Wahl 2005). This suggestion is based on the observation that mdm2 destabilization coincides with the duration of p53 response, and that blocking the degradation of mdm2 prevented p53 activation in DNA damaged cells (Stommel and Wahl 2004). The mdm2 phosphorylation is dependent upon damage activated kinases and an intact functional mdm2 RING domain (Stommel and Wahl 2004). How this phosphorylation destabilizes mdm2 is not yet clear, however, a possible role of RING domain interacting protein mdmX that prevents mdm2 auto-ubiquitination has been suggested (Kawai, Wiederschain et al. 2003; Stommel and Wahl 2005). These studies suggest that mdm2 destabilization during DNA damage contributes significantly to the inability of mdm2 to block p53 activation during a damage response. The available additional evidence showing how the modest alterations in levels of mdm2 abundance have a profound effect on damage-induced activation of p53 further supports this concept (Tergaonkar, Pando et al. 2002; Mendrysa, McElwee et al. 2003).

A revised model for p53 activation

Based on the observations mentioned in the paragraph above, a new model has been proposed for p53 activation by DNA damage (Stommel and Wahl 2004; Stommel and Wahl 2005). This model (Fig-2.13) is centered on mdm2 destabilization in response to DNA damage, which is thought to be necessary for p53 transcriptional activation.
It is suggested that in unstressed cells, p53 is kept in an inactive state by mdm2. Mdm2 and mdmX heterodimerize via their respective RING domains (grey ring) and are bound to the N-terminal p53 transactivation domain inactivating it and are capable of ubiquitinating (white circles) the C-terminus of p53 targeting it for degradation (as shown in fig-13: 1). The mdm2-mdmX heterodimer may engage an E2 ubiquitin ligase to enable polyubiquitination. Soon after DNA damage, ATM and other DNA damage-activated kinases phosphorylate (grey ovals) both p53 and mdm2. However, despite p53 phosphorylated at N-terminal residues (such as ser15, 20), it is inactive because mdm2 (and mdmX) are still bound to it (as shown in Fig-13: 2). The peak response to DNA damage correlates with auto-ubiquitination and degradation of mdm2 (and mdmX) and consequent stabilization and activation of p53 (as shown in Fig-2.13: 3). The active p53 interacts with the transcriptional machinery in order to activate the downstream genes to bring about the cellular response in the form of cell cycle arrest or apoptosis or DNA repair. The active p53 also induces the expression of mdm2 but the newly synthesized protein has reduced affinity for p53 due to N-terminal phosphorylation of p53 and, in addition, the continued modification of mdm2 by the ongoing damage kinase activity renders it unstable thus keeping p53 active to control the damage. The half-life of mdm2 in DNA damaged cells is about 5 min. Later, once the DNA damage is successfully repaired, the kinases become inactive and the mdm2 mRNA accumulated in response to p53 activation gets translated in a stable form that hetreo-dimerizes with mdmX and inactivates p53 (as shown in Fig-2.13).
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Fig-2.13: Revised model for p53 activation.
Functions of p53

The activated p53 binds to a specific DNA sequence, termed the p53-responsive element (RE), composed of (RRRCWWGYYY-spacer of 0-21 nucleotides-RRRCWWGYYY), where R is a purine, W is A or T, and Y is a pyrimidine. These two degenerate 10bp sequences separated in the genome by a variable length spacer are required to regulate the p53-responsive genes.

1) Transcription factor
The p53 protein is a transcription factor (Farmer, Bargonetti et al. 1992; Unger, Nau et al. 1992) that enhances the transcription of various genes that contain p53-dependent DNA-responsive element. These include p21WAF1/Cip1 (el-Deiry, Tokino et al. 1993), GADD45 (Kastan, Zhan et al. 1992), mdm2 (Momand, Zambetti et al. 1992), IGF-BP3 (Buckbinder, Talbott et al. 1995), and Bax (Miyashita and Reed 1995)

2) DNA repair to maintain genomic integrity
The core domain of the p53 molecule harbours two mutually exclusive biochemical activities (Fig-2.14), DNA sequence specific binding activity for its role as a transcription factor and 3’-5’ exonuclease activity involved in the DNA repair mechanism (Mummenbrauer, Janus et al. 1996). The exonucleases are required for the DNA replication, repair and recombination. It has been shown that the modification of p53 which leads to activation of its sequence-specific DNA-binding activity results in inactivation of its 3’-5’ exonuclease activity (Janus, Albrechtsen et al. 1999).
Based on the above findings, a dual role model has been suggested for p53 in maintaining genomic integrity (Janus, Albrechtsen et al. 1999). In its non-induced form, p53 is probably involved in prevention and repair of DNA damage through its 3’-5’ exonuclease activity and upon induction by exogenous DNA damage, p53 is involved in tumour suppressing activities by transactivating other genes that interact with the replication machinery.
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Fig-2.14: Dual role of p53 in maintaining genomic integrity

3)	Tumour suppressor

The ability of p53 to eliminate damaged cells by apoptosis is vital for the optimal regulation of cell proliferation (Kerr, Wyllie et al. 1972). Upon activation by various external and internal stress signals, p53 induces either growth arrest of viable cells or apoptosis of irreversibly damaged or transformed cells (Jin and Levine 2001) and the latter activity is crucial for tumour suppression (Bates and Vousden 1999). What influences p53 to induce cell cycle arrest or apoptosis is not fully understood, various influencing factors include the levels of p53, type of stress signal, the type of cell, the degree of damage and the type of co-activators expressed (Fig-2.15) (Sionov and Haupt 1999). 

a) p53 and apoptosis
Apoptosis proceeds mainly through two pathways: the extrinsic pathway, which works via cell surface death receptors and the intrinsic pathway, which centres on mitochondria and is primarily regulated by the bcl-2 family. Though p53 can modulate key points in both the extrinsic and intrinsic pathways of apoptosis, it has been suggested that p53 involves primarily the intrinsic pathway while the extrinsic pathway is used to augment the response (Fridman and Lowe 2003). This control of apoptosis involves both transcription-dependent and independent mechanisms. 

b) p53 and growth arrest
p53 mediates growth arrest through regulation of crucial checkpoints during both the G1 and G2 phases of the cell cycle.

p53-dependent G1 arrest: This is mediated by transactivation of the waf1 gene that encodes for the small kinase activator p21cip1/waf1. p21 is a universal Cdk inhibitor and by doing so maintains retinoblastoma protein in an hypophosphorylated form (pRb) which in turn blocks the E2F mediated transcription of genes required for entry into S phase resulting in accumulation of cells in G1 phase (el-Deiry, Tokino et al. 1993; Xiong, Hannon et al. 1993; Dulic, Kaufmann et al. 1994).

p53-dependent G2 arrest: This is mediated by two target genes, namely 14-3-3 and to a lesser extent GADD45. 14-3-3 negatively regulates Cdc25C, which is a protein phosphatase that controls entry into mitosis by dephosphorylating the cyclin B/Cdc2 protein complex (Peng, Graves et al. 1997). GADD45 directly interacts with Cdc2 and disrupts cyclin B/Cdc2 complex, thus resulting in cells arrested at G2/M transition (Wang, Zhan et al. 1999).
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Fig-2.15: Model for apoptotic response to various stimuli.
Decision Making: growth arrest or apoptosis
What determines whether p53 activation induces apoptosis or cell cycle arrest? This is not completely understood, however various factors that can influence the decision include the cell type, the cellular microenvironment (cellular context at the time of exposure of stress), the type of stress signal, and p53 expression levels (Sionov and Haupt 1999; Balint and Vousden 2001) . For example, following -irradiation p53 induces apoptotic genes (DR5, Bid, PUMA and Noxa) in radiosensitive tissues of spleen and gut, while high levels of p21 induce growth arrest in radioresistant tissues (Fei, Bernhard et al. 2002). Lymphoma cells undergo p53-dependent apoptosis in response to chemotherapy, but if these lymphoma cells overexpress bcl-2 (anti-apoptotic), the cells undergo p53-dependent cellular senescence (Schmitt, Fridman et al. 2002). Similarly different p53 activating stimuli (e.g. -radiation vs. UV) activate selective and unique expression of target genes resulting in different outcomes (Zhao, Gish et al. 2000).
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Fig-2.16
The p53 functional circuit (Jin and Levine 2001). The functional signal transduction circuit consists of upstream mediators that activate p53 in response to various stress signals, the core regulation components that play a key role in maintaining p53 levels, and the downstream effectors that essentially form the cellular response to the preceding stress.




Regulation of p53

The core regulatory circuit, as shown above in Fig-16, consists of p53, mdm2, p14ARF and E2F-1. These form two feedback loops, one between p53 and mdm2 (Freedman, Wu et al. 1999) and the other between p14ARF and E2F-1. These two loops interact by p14ARF interacting with mdm2 and p53 inhibiting the transcription of ARF gene (Jin and Levine 2001). This complex circuit is essential for maintaining and regulating p53 levels and activities and thereby, the defects in this circuit are the common mechanisms of tumorigenesis.

mdm2-p53 interaction
The mdm2 gene is transcriptionally induced by p53 after its stabilization by DNA damage (Barak, Juven et al. 1993; Wu, Bayle et al. 1993) and mdm2 in turn inhibits p53 activity. The amino-terminus of mdm2 binds to the amino-terminus (transactivation domain) of p53 (Oliner, Pietenpol et al. 1993) and results in inhibition of p53 transcription functions thereby blocking the tumour suppressor function of p53 (Chen, Lin et al. 1995; Chen, Wu et al. 1996) and thus classifying itself as a potential oncogene, when overexpressed. In addition, mdm2 also targets p53 for degradation by ubiquitination (Haupt, Maya et al. 1997; Kubbutat, Jones et al. 1997; Tao and Levine 1999). Because of this function, mdm2 is thought to play a role in regulating the low steady-state levels of p53 in normal cells (Freedman and Levine 1999). Whether p53 degradation occurs only in cytoplasm and so requires nuclear export is a subject of controversy (Roth, Dobbelstein et al. 1998; Xirodimas, Saville et al. 2001; Shirangi, Zaika et al. 2002; O'Keefe, Li et al. 2003). It is now being suggested that p53 degradation can occur either in nucleus or the cytoplasm and nucleo-cytoplasmic shuttling is not a pre-requisite for p53 degradation, and the structure of p53 is more important than subcellular localization for mdm2-mediated p53 degradation i.e. tetrameric (wildtype) form of p53 is degraded more efficiently than the monomeric or dimeric (mutant) forms (Stommel and Wahl 2004). The rise in p53 levels after DNA damage correlates directly with the level of mdm2 expression such that p53 can overcome inhibition by mdm2 for its appropriate reparative cellular responses (Kubbutat, Jones et al. 1997). The induction of mdm2 consequent to a rise in p53 occurs with due latency in order to allow for p53 action and the mechanisms regulating mdm2-induced degradation may actually dictate the extent and duration of p53 response. Thus, mdm2 and p53 form an auto-regulatory feedback loop whereby p53 limits its own activity through production of mdm2. 

However, recent studies suggest a potentially predominant role of mdm2 destabilization (and not of p53 phosphorylation as was initially thought) for p53 activation in response to DNA damage (Stommel and Wahl 2004; Stommel and Wahl 2005). The available additional evidence showing how the modest alterations in levels of mdm2 abundance have a profound effect on damage-induced activation of p53 further supports this concept. Studies have shown a reduction in p53 response to DNA damage following NF-B mediated increase in mdm2 levels (Tergaonkar, Pando et al. 2002) and a significant increase in radiosensitivity following a 50% decrease in mdm2 levels (Mendrysa, McElwee et al. 2003).


p53 and breast cancer

Breast tumours expressing a high amount of p53 (as measured by IHC) are more frequently ER-negative and progesterone receptor (PgR)-negative. They are also associated with a high proliferation rate, high histological and nuclear grades, aneuploidy, and poorer survival. A high p53 level is frequently observed in tumours over-expressing HER2  (Feki and Irminger-Finger 2004). Cancers with p53 mutations (both with or without HER2 amplification) are more likely to be ER- and PgR-negative, more likely to be grade 3 for both histological and nuclear grade, and less likely to have lobular subtype (Rahko, Blanco et al. 2003; Bull, Ozcelik et al. 2004). 

The prognostic and predictive value of high p53 expression in breast cancer, as evaluated by IHC, has been found to be weak in a meta-analysis (Barbareschi 1996), while several studies have revealed the strong prognostic significance of p53 mutations (reviewed in (Borresen-Dale 2003). A meta-analysis (Pharoah, Day et al. 1999; Petitjean, Achatz et al. 2007) confirmed that mutations in the Tp53 confer a worse overall and disease-free survival in breast cancer cases, an effect that is independent of other risk factors. 
Breast cancer cell lines with an endogenous mutant p53, while dramatically heterogeneous in their behaviour (Lowe, Ruley et al. 1993), still tend to be less sensitive than the wild-type p53 lines to most of the clinically used anticancer agents. Interestingly, however, mitotic spindle poisons were found to act independently from the p53 status.
Despite expressing a similar wild type p53 status, luminal epithelial-like cells (as defined on micro-arrays) seem to respond to some chemotherapeutic drugs suvh as 5FU and doxorubicin, to a higher qualitative and quantitative extent than basal/myoepithelial-like cells. A crucial indication of the experimental findings is that the role of p53 alone in determining sensitivity/resistance to cytotoxic drugs is limited: the individual molecular pathology and differentiation of a given cancer line prevail over any average trend (Lacroix, Toillon et al. 2006). 
It is presently unclear whether the p53 status may provide an advantage in resistance to radiotherapy. Clinical studies examining the relationship between clinical radiosensitivity and tumour p53 status have largely failed to demonstrate a significant effect. 

p53 and oestradiol (E2)

In-vitro studies
Various in-vitro studies have shown that E2 upregulates p53 expression in a concentration-dependent manner (Hurd, Khattree et al. 1995; Moudgil, Dinda et al. 2001; Okumura, Saji et al. 2002). It is well established that cell lines require oestrogen for their growth so, it is difficult to determine whether increases in p53 is a consequence of oestrogen induced cell proliferation or a direct effect of oestrogen supplementation. There is evidence to suggest that the increase in p53 levels is due to changes at post-transcriptional level because there is no accompanied change in p53 mRNA levels in response to E2, thereby suggesting a direct effect of oestradiol on p53 expression (Okumura, Saji et al. 2002). The stability of mutant p53 is not affected by E2, even in ER-positive cells.
Mechanism of p53 up-regulation
Molinari et al suggested that oestradiol induces functional inactivation of p53 by causing nuclear extrusion of p53. They correlated the intracellular redistribution of p53 to a reduced expression of p21 and to the presence of degradation products of p53 in the cytoplasm (Molinari, Bontempo et al. 2000). 
In contrast, recent studies suggest that oestradiol induces accumulation of active p53. p53 is rapidly degraded when MCF-7 cells are transferred to E2-depleted medium and E2 treatment significantly delays p53 degradation thus promoting its intranuclear accumulation (Okumura, Saji et al. 2002). The antioestrogens ICI 164,384 and OHT (hydroxy-tamoxifen), which also compete for ER binding sites with E2, block the E2-induced p53 response in cell cultures, indicating that the effect is ER mediated (Hurd, Khattree et al. 1997). According to Moudgil et al, oestrogen induces p53 gene expression and this effect is indirect and mediated by c-Myc transcription (Fig-2.17). The E2-ER complex interacts with the ERE present in the c-Myc gene, which responds by increasing c-Myc mRNA leading to amplified c-Myc protein levels. The c-Myc interacts with the P1 promoter region of p53 gene (which contains c-Myc responsive element) leading to increased synthesis of the tumour suppressor protein (Moudgil, Dinda et al. 2001). All these actions are blocked by the antioestrogen suggesting an involvement of ER-mediated mechanism.
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Fig-2.17: A hypothetical model for explaining oestrogen regulation of p53 in breast cancer cells.

In-vivo study

A research study in MCF7 mouse xenograft model, conducted at University of Dundee (Ziyaie 2003) demonstrated a distinct pattern in p53 protein immuno-reaction in response to alterations in serum hormone concentrations. p53 levels reduced in response to increasing levels of serum oestrogen, and rose concomitant with declining levels. A similar trend was observed with p21WAF1 expression. The relationship between p53 and serum oestrogen levels has not been shown in humans. If this relationship is borne out in humans, this would suggest a potential tumour behaviour modifying role of oestrogen, and timing of chemotherapy related to serum oestradiol levels could influence the effectiveness of anti-cancer agents in pre-menopausal women with breast cancer.








CHAPTER-3
MATERIAL & METHODS






Patients 

Women with a diagnosis of primary, operable, symptomatic breast cancer were eligible to be included in the study (Fig-3.1). A total of 99 patients with invasive breast cancer were included in the study. Of the 99 patients with invasive breast cancer, 47 were premenopausal and 52 were postmenopausal. Of these, 32 pre-menopausal and 33 post-menopausal women had paired samples of breast cancer biopsy and venous blood taken at diagnosis and later at the time of resectional surgery. The samples were collected at two time points to study the change in expression of tumour proteins, if any, with the change in serum oestradiol levels in pre-menopausal women.  The rest of the patients included had tissue samples and blood taken at one time point only i.e. at resectional surgery.

The pre-menopausal women with primary invasive ductal carcinoma of breast and planned to undergo surgery without any neo-adjuvant therapy formed the study group. The surgery was scheduled with an intention to time the samples (tumour tissue and blood) to two different points in the menstrual cycle, however with a due consideration not to delay the treatment. The post-menopausal women formed the control group, with no change in the internal endocrine influences over the time of study. Women taking oral contraceptives or HRT were excluded and patients were consented prior to entry into the study. Full clinical data including pathological details, therapies and follow-up was collected on these patients prospectively.

The menopausal status of the patient was determined by the patient’s history and was later confirmed by venous blood hormonal analysis of FSH, LH, progesterone and oestrogen. The stage of the tumour did not form the eligibility criteria; only those with known distant metastasis were excluded, as they did not undergo surgery. Patients were included in the pre-menopausal group for the analysis if they were clinically and biochemically pre-menopausal at the time of diagnosis. Peri-menopausal patients (within 1 year of menopause) were excluded from the study.
The Tayside Ethical Committee, Ninewells Hospital & Medical School, Dundee formally approved the study (letter dated 18th September 2001).


99 patients with invasive breast cancer included in the study


Premenopausal patients: 47			Postmenopausal patients: 52

  	Paired samples of tumour biopsy
 	& blood at two time points

Premenopausal: 30					Post menopausal: 33


			Fig-3.1: Consort diagram for this study.


Samples

Samples comprised frozen breast cancer tissue for molecular studies and formalin fixed breast cancer tissues for tissue micro-array and immunohistochemistry from both time points; serum was drawn for 17- oestradiol, progesterone, FSH, LH. Statistical power analysis suggested that 30 paired samples each from study and control groups should provide sufficient data for 80% confidence at the 5% level.

Frozen Tissue Samples

Core Biopsy: This corresponded to tissue at the first time point, which was collected at the time of diagnosis. The core biopsy technique involves obtaining very thin cores (diameter of 3-5 mm) of tissue from the cancer using a core-cut needle under a local anaesthetic. 4-6 cores were obtained as in routine practice for diagnosis and 1-2 extra cores (for research) were obtained from patients in the study. These cores were put in labelled cryovials and snap frozen immediately in liquid nitrogen and thereafter stored in the refrigerator at –80C in the tumour bank. This tissue can be subjected to a variety of molecular studies at a later date.

Surgical specimens: The tissue corresponding to the second time point was derived from the excised breast tissue at the time of surgery. The excised surgical specimen i.e. mastectomy or wide local excision were sent fresh to pathology, where they were dealt with almost immediately by the pathologist. The tumour within the breast tissue was identified by the pathologist and small sections of tumour were spared for research purposes after making sure that the diagnostic requirements were not compromised. The tissue thus obtained was stored in a similar manner as core biopsy specimen i.e. put in labelled cryovials and snap frozen immediately in liquid nitrogen and thereafter stored in the refrigerator at –80C in the tumour bank. The time delay between excising surgical specimen and obtaining fresh tissue for cryopreservation was kept to minimum possible (within 60-90 minutes) by ensuring quick transport of specimen to the pathology department and availability of the pathologist to process the specimen.

Paraffin fixed tissues

The pathology samples corresponding to the two time points, i.e. diagnosis and surgery, were archived in the pathology department after each specimen had been subjected to detailed pathology examination. The paraffin blocks of the cancers included in the study were retrieved in order to study the expression of various proteins in breast cancer using immunohistochemistry. A tumour micro-array (TMA) was constructed from the surgical specimens (second time point) of all the patients under the guidance of Dr. Colin A. Purdie (Consultant Pathologist) and the MRC/CRUK Human tissue/tumour bank in Dundee (Mr. G. Thomson). However, the core biopsy specimens were processed individually as whole tissue sections (WTS) because of the limited thickness of tissue available making TMA a difficult option with these core biopsies.

Serum

Venous blood samples were obtained from the patients at the time of their diagnosis and during surgery corresponding to the two time points. These were sent to the Department of Biochemistry, Tayside University Hospitals Trust for measurement of 17- oestradiol, progesterone, FSH and LH in the pre-menopausal women and 17- oestradiol and progesterone only in the post-menopausal women. The samples were centrifuged to extract serum, which was stored at -20C in the department. The assays were run in batches such that the paired samples were analysed simultaneously. The laboratory reference values are as in table-3.1.


Menopausal status	Plasma concentrations
	Oestradiol (pmol/L)	Progesterone (nmol/L)	FSH (U/L)	LH (U/L)
Pre-menopausal	Up to 700	>30 (luteal peak/day 21) *	1.1-9.6	0.8-12.0
Post-menopausal	Low	Low	>25	>15


Table-3.1: Serum hormone levels in pre- and post-menopausal women.
* These levels apply to luteal peak only.
					






Estimation of 17- oestradiol

The17- oestradiol was measured using the electrochemiluminescence immunoassay (ECLIA) on Modular Analytics E170 analyzers. This test employs a competitive test principle using a polyclonal antibody specifically directed against 17- oestradiol. The duration of assay is 18 minutes. The steps involved in the test are detailed below: 
1.	1st incubation: 35 µl of sample is incubated with an oestradiol-specific biotinylated antibody resulting in an immunocomplex, the amount of which is dependent upon the analyte concentration in the sample.
2.	2nd incubation: The streptavidin-coated paramagnetic microparticles and an oestradiol derivative labeled with a ruthenium complex is added to occupy the still-vacant sites of the biotinylated antibodies resulting in formation of an antibody-hapten complex. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin.
3.	The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode, the unbound reagent and sample are washed away by ProCell.
4.	In the ECL reaction, the conjugate is a ruthenium based derivative and the chemiluminescent reaction is electrically stimulated to produce light. The amount of light produced is indirectly proportional to the amount of antigen in the patient sample. The advantage of electrically initiating the chemiluminescent reaction is that the entire reaction can be precisely controlled.
5.	The evaluation and calculation of concentration of the antigen are carried out by means of a calibration curve that was established using standards of known antigen concentration.
Pilot Study

The pilot data consisted of paired samples from 8 pre-menopausal and 21 post-menopausal patients. Using paraffin fixed tissues derived from the surgical specimen (corresponding to the second time point), a tissue micro-array was constructed initially using up to 6 cores from each patient in the pilot group. The cores from each cancer consisted of 1 core from normal breast tissue, up to 2 cores from invasive ductal cancer, where identified, 1 core from DCIS where identified and where present, 1-2 cores from metastatic lymph nodes, where present. The core biopsy specimens corresponding to the first time point was sectioned individually (whole tissue sections), as these biopsy specimens, being thin are not suitable for TMA construction. The slides corresponding to two time points i.e. TMA sections and WTS were then stained with the various antibodies. The micro-array was first examined for the adequacy of the number of cores to represent the corresponding tissue and to assess its comparability with WTS. It was shown that the TMA projected an adequate representation of invasive cancer provided there were at least 2, preferably 3 good quality cores on TMA. This is important considering the fact that breast cancer can be fairly heterogenous. This was followed by an amendment in the number and types of cores from each patient to be included in the TMA in order to make it a true representative of the corresponding whole tissue. The subsequent TMA consisted of at least 4, preferably 6 cores of tumour tissue (only) from each cancer.
Tissue microarray

The paraffin wax-embedded tissue samples were used to construct tissue microarrays (TMA) (Fig-3.2). One whole tissue section from each specimen was stained with hematoxylin-eosin stain and examined for the presence of tumour. The optimum tumour areas were marked to obtain the cores for making a TMA.  TMAs were constructed using a standard instrument (Beecher instruments, Silver Springs, MD, USA) (Fig-3.3). Each recipient block consisted of at least 4, preferably 6 cores of cancer tissue from each patient, each core measuring 0.6 mm in diameter.








Fig-3.2: Picture demonstrates TMA (tumour microarray) slide with multiple breast cancer cores from different patients and the appearance of a core under microscope (10X) after immunohistochemical staining.

An initial TMA was constructed for a pilot series (29 patients) containing 2 cores of invasive cancer from each case (Camp, Charette et al. 2000; Gillett, Springall et al. 2000); at least 1 readable core was obtained in majority of the cases. However only 55%-65% concordance was found between TMA and whole tissue sections when immunoassayed for ER and PR. It was then decided to obtain 4-6 cores of invasive cancer from each case in order to ensure at least 2, preferably 3 readable cores from each specimen. Thereafter a repeat TMA with at least 4 cores from each cancer showed 95% concordance for ER and PR when compared with whole tissue sections (table-3.2). This ensured adequate representation of the tumour on TMA sections considering the heterogenous nature of breast cancer. The immunohistochemical staining was analysed by two independent observers (PGR and Dr. C.A. Purdie). Greater than 95% concordance was seen between the findings of the two observers and the discordant results were re-examined to mutual consensus.



			Fig-3.3: Beecher’s instrument

Four TMA blocks were constructed, the first consisting of pilot series of 29 specimens (8 from pre-menopausal and 21 from post-menopausal patients), a second with 35 (all from pre-menopausal), a third with 31 (all from post-menopausal) and a fourth consisting of 14 cancers (7 from pre-menopausal and 7 from post-menopausal patients). The sequential construction of TMAs helped the study to proceed at a steady pace as the patient recruitment and sample collection at two time points was going on simultaneously.


No. of cores from each cancer	Number of readable cores achieved	Concordance with whole tissue sections
2	1-2	55%-65%
4-6	At least 2-3	95%

Table-3.2
Number of representative cores required from each cancer on TMA in order to achieve 95% concordance with the whole tissue sections. This was worked out by analysing immunohistochemistry scores for ER and PR and comparing them with those available from the corresponding diagnostic specimen.


Clinical information

Histopathology: The detailed pathology results obtained from the resectional specimen were retrieved from the pathology records at the end of the study. The information collected included the type of tumour (invasive or DCIS, ductal or lobular carcinoma), tumour size, tumour grade, lymphovascular invasion, and axillary lymph node involvement.
Prognostic Index: The Nottingham Prognostic index (NPI) (Galea, Blamey et al. 1992) was derived for each tumour using tumour grade, histological tumour size and pathological node status. 
NPI = (tumour size in cm X 0.2) + lymph node stage (1 = no nodes, 2 = 1 to 3 nodes positive, 3 = 4 or more nodes involved) + grade (1, 2 or 3).  Originally forming 3 prognostic groups (good, moderate, poor) the NPI is now used to place patients in one of 5 prognostic groups (Blamey 1996).

Prognostic group			NPI			10 yr survival (%) Excellent				<2.4				94
Good 					<3.4				83
Moderate I				<4.4				70
Moderate II				<5.4				51
Poor					>5.4				19

Treatment received: The information about the other forms of treatments received following surgery i.e. chemotherapy, radiotherapy or hormonal therapy was collected.
Follow-up/ Recurrence/ Deaths: Follow-up data with regards to tumour recurrence, metastasis and death was obtained from the breast cancer patients’ follow-up database maintained by the Tumour Bank at Ninewells Hospital, Dundee. This was a prospective study, therefore long term follow-up data could not be obtained.
Immunohistochemistry

The paraffin-embedded tissue sections were retrieved from the Department of Pathology. The core biopsy specimens were mounted on polylysine-coated glass slides to make whole tissue section whereas a TMA was constructed from the surgical specimens.  
All the slides were stained using either of the two following staining instruments:
a)	DakoCytomation TechMateTM: this equipment was used to stain whole tissue sections obtained from core biopsies. This is an efficient and automated system allowing staining of upto 200 slides (Fig-3.4).


Fig-3.4: DakoCytomation TechMateTM


b)	Dako Autosatiner Universal Staining System (Fig-3.5): This is more research oriented equipment specifically used for TMAs and stains upto 48 TMA sections in one cycle. Techmate depends upon capillary action between the two opposed slides for the different reagents to work on the tissue on the slides and tends to be parabolic or follows the outline in whole-tissues sections. In case of TMA, the tissues being small and multiple cores and discontinuous, the reagents do not follow the ouline of tissue and tend to miss out on some of the peripheral cores leaving them unstained on Techmate, therefore this equipment is not considered suitable for staining TMAs.


		Fig-3.5: Autostainer.

Staining Method   

Paraffin was removed from the slides by heating them at 570C for 1 hour. This was followed by gradual hydration through graded alcohol. The antigen retrieval required incubation in citrate buffer (10nM: pH 6.0) for a cycle of 15 minutes under pressure in a microwave oven (750 W)  in most cases (unless indicated otherwise). The slides were then cooled down gradually and stained. All through, care is taken to prevent air-drying of slides. 
Two detection kits are available commercially, Chemmate Detection Kit, DakoCytomation and  Vectastain Elite ABC kit, Vector laboratories, Burlingame, CA, USA. The chemmate can be used for staining with both DakoCytomation Techmate and Autostainer Instruments, while Vectastain is compatible with Autosatiner only. Both the kits were tested initially on Autostainer to assess the comparability. The quality of staining was observed to be different with the two kits so to ensure the comparability of staining performed on Techmate and Autostainer, it was decided to use Chemmate Detection Kit, Peroxidase/DAB, Rabbit/Mouse, DakoCytomation.. The kit is based on the LSAB (labelled Streptavidin-biotin) method and is employed in a three step procedure. The first step was incubation of the tissue with an optimally diluted primary rabbit or mouse antibody, the second step required incubation with ChemMate Link, Biotinylated Secondary Antibody (AB2), and the third step was incubation with ChemMate Streptavidin Peroxidase (HRP). Finally, the reaction was visualized by a DAB+ chromogen. 
The reagents used were:
a)	Primary antibodies
b)	Reagent A (yellow colour): ChemMate Link, Biotinylated Secondary Antibody (AB2). This contains biotinylated goat anti-mouse and anti-rabbit immunoglobulins. This reagent reacts equally well with rabbit and mouse immunoglobulins, thus only one secondary reagent is required for rabbit or mouse primary antibodies (unlike Vectastain).                                                                                                                                                                                                                                                                                                                                                                                                                                                  
c)	ChemMate Peroxidase blocking soloution: to block the endogenous peroxidase activity.
d)	Reagent B: ChemMate Streptavidin Peroxidase (HRP or ChemMate tertiary). This contains streptavidin conjugated to horseradish peroxidase.
e)	Enzyme substrate: This is prepared by diluting the concentrated ChemMate DAB+ chromogen (3,3’-diaminobenzidine tetrahydrochloride) with the ChemMate HRP substrate buffer (1:50). This gives a brown colour at the site of target antigen.
f)	0.5% CuSO4: this enhances the effect of chromogen.
g)	20% haematoxylin: to counterstain the nuclei blue.
A negative control was run in parallel with each test section to exclude non-specific reactivity. A positive control was also included to ensure the quality of staining.
After the staining cycle is completed, the slides are again taken through graded alcohol, this time in a reverse order in order to dehydrate them followed by application of coverslip.
The details of the various antibodies used in the study along with the working dilutions are outlined in table-3.3. The dilutions for the antibodies were worked out in our laboratory by trying out different dilutions (usually 3-4 dilutions around the one recommended by the manufacturer) on the human breast cancer specimens. The standard antigen retrieval method was used for all the proteins studied i.e. microwave heating under pressure in citric acid buffer for 15 minutes. In addition to the antibodies mentioned in the table, mdm2 (murine double minute 2) was also tested. It was tried in different concentrations, however the staining was inconsistent and proved difficult to work with so after consultation with the experienced scientists, it was decided to abandon testing the expression of mdm2.
Antigen	Antibody	Ag Retrieval	Specificity	Dilution	Source
p53	DO-1	MWP CA 15’	monoclonal	1:50	(Vojtesek, Bartek et al. 1992)
p53 	NCL-p53-PHOS (Ser392) (FP3-2)	MWP CA 15’	monoclonal	1:25	Novocastra Laboratories, Newcastle upon Tyne,UK
p21WAF1/Cip1	Anti-human p21 Ab         (M 7202)	MWP CA 15’	monoclonal	1:100	DakoCytomation, Glostrup, Denmark
Bcl-2	Bcl-2 Ab clone 124	MWP CA 15’	monoclonal	1:500	DakoCytomation, Glostrup, Denmark
Bax	Anti-human Bax Ab (A3533)	MWP CA 15’	polyclonal	1:200	DakoCytomation, Glostrup, Denmark
ER	NCL-L-ER-6F11	MWP CA 15’	monoclonal	1:250	Novocastra Laboratories, Newcastle upon Tyne,UK
PgR	NCL-L-PGR-312	MWP CA 15’	monoclonal	1:400	Novocastra Laboratories, Newcastle upon Tyne,UK
HER-2	NCL-L-CB11	MWP CA 15’	monoclonal	1:700	Novocastra Laboratories, Newcastle upon Tyne,UK
Cyclin D1	NCL-CYCLIND1-GM (P2D11F11)	MWP CA 15’	monoclonal	1:40	Novocastra Laboratories, Newcastle upon Tyne,UK
Mcm2	Anti-mcm2 antibody	MWP CA 15’	monoclonal	1:40	Courtesy: MRC Research Centre, Cambridge
Geminin	NCL-L-Geminin (Research) (EM6)	MWP CA 15’	monoclonal	1:20	Novocastra Laboratories, Newcastle upon Tyne,UK
Ki67 	VP-K452 anti-human Ki67 (VP-K452)	MWP CA 15’	monoclonal	1:200	Vector Laboratories Inc,Burlingame, CA 94010 USA

Table-3.3: List of antibodies used for immunohistochemistry
 (Monoclonal antibodies are raised in mouse, polyclonal are raised in rabbit)
MWP CA 15’: antigen retrieval requires microwave heating under pressure in citric acid buffer (10nM, pH 6.0) for 15 minutes.

Scoring System

A scoring system was used to quantify the expression of various proteins based on the Quick Score method (Detre, Saclani Jotti et al. 1995). This method was used by the pathologists in the host institution for scoring of receptor expression (ER, PR) on routine diagnostic breast cancer specimens at the time of the project. The method required assessment of two parameters and a final score was calculated by multiplying the two parameters.
a)	Labelling index: This refers to the percentage of cells staining positive for a particular protein. This was divided into 6 groups from 1 to 6 as tabulated below.

Score	    % positively staining malignant cells 
1	1-4
2	5-19
3	20-39
4	40-59
5	60-79
6	80-100


b)	Intensity of staining: This is classified into 0, 1, 2 and 3 in the increasing order of the intensity of the stain (Fig-3.6).




Fig-3.6	
Immunohistochemistical staining exhibiting different intensity of nuclear staining, intensity of 1(top), 2 (middle) and 3 (bottom) under high power microscopy
Both the intensity and labellingindex  were analysed by light microscopy and therefore, it is termed a semi-quantitative method of assessment. For analytical purposes, either the labelling index or the quickscore (obtained by multiplying the labelling index score by the average intensity of the positively staining cells) were used.
For ER, PgR, Cyclin D1, mcm2, geminin, p53, FP3, p21, the nuclear staining of the invasive tumour cells was scored as positive (Fig-3.7a).
For bax and bcl-2, the cytoplasmic staining of the invasive tumour cells was scored as positive (Fig-3.7b). 
For HER-2, the membrane staining of the cancer cells was considered to be positive. The scoring system used for HER-2 was as follows:

	Staining pattern	Score (Impression)
No specific membrane staining	- (negative)
Membrane staining in less than 10% of cells or cytoplasmic staining	1+ (negative)
Specific membrane staining in more than 10% of cells	2+ (positive)
Strong specific membrane staining in majority or all cells	3+ (positive)


All the slides were scored independently by two observers (PGR and Dr. Colin Purdie), one of them being a consultant specialist breast histopathologist (Dr. Colin Purdie). Greater than 95% concordance was seen between the findings of the two observers and the discordant results were re-examined to mutual consensus.





			
					Fig-3.7a
Immunohistochemistry depicting nuclear staining for ER in breast cancer (magnification 10X).












					Fig-3.7b
Immunohistochemistry depicting cytoplasmic staining for bax (above) and bcl-2 (below) in breast cancer.

FISH (Fluorescence In Situ Hybridization)

This technique was used to detect the amplification of cyclin D1 gene (CCND1) in patients of breast cancer. FISH was performed on paraffin-embedded sections obtained from the tumour microarrays (TMA) constructed during the study for the purpose of high throughput analysis of various molecular markers in breast cancer and was performed in conjunction with the NHS Human Genetics Unit at Ninewells Hospital & Medical School, Dundee.
The various steps involved in the FISH procedure were as follows:
A. Pre-treatment of formalin-fixed paraffin-embedded tissue sections: In this step, the tissue sections (4m thick on positively charged slides and baked overnight at 56C) were deparaffinised and target DNA exposed by permeabilising tissues using sodium thiocyanate (NaSCN) pre-treatment and protease digestion.
Equipment						Solutions/ Reagents
80C waterbath					Xylene		
37C waterbath					100% ethanol
Microcentifuge					0.2N HCl
Glass coplin jars and lids in fume hood		0.01N HCl Buffer (Vysis)
Plastic coplin jars and lids	2x SSC (sodium chloride & sodium citrate)
Hot plate at 45C 					Sodium thiocyanate (Vysis)
22x50mm cover slips					Protease (Vysis)
Fine balance						Distilled water
Forceps							DAPI II Antifade (Vysis)
Gilson pipette 20l					
Ice bucket
Florescent microscope
25 mg of protease powder (2500-3000U/mg, lyophilised)
Protease solution 		50 ml of 0.01N HCl buffer (pepsin buffer)

DAPI (4'-6-Diamidino-2-phenylindole) forms fluorescent complexes with natural double-stranded DNA.

Steps:
The tissue sections were deparaffinised by immersing the slides twice in xylene in a fume hood for 10 minutes each at room temperature.
The slides were then immersed twice in 100% ethanol for 5 minutes, each time at room temperature, to wash off the wax.
The slides were dried on a hot plate at 45C and then treat them with 0.2N HCl for 20 minutes at room temperature.
This was followed by immersing the slides in distilled water and then 2xSSC for 3 minutes each time.
The slides were then treated with NaSCN pre-treatment solution in 80C waterbath for 30 minutes.
The slides were then washed with distilled water and 2xSSC.
This was followed by digestion of tissue in protease solution at 37C for 20 minutes.
The slides were then washed with 2xSSC followed by graded (cold) ethanol treatment i.e. 70%, 85% and 100% ethanol each for 2 minutes on ice.
The slides were then dried and to assess digestion, 20l DAPI is applied under a coverslip and viewed under fluorescence microscope.If the tissue was under-digested, the protease treatment was repeated. 
If the digestion was satisfactory, the slides were washed with distilled water and 2xSSC followed by graded ethanol treatment on ice to proceed to the denaturation step.

B. Denaturation of DNA: Formamide was used to denature DNA to allow probe binding for the in situ hybridisation methods. Formamide effectively reduces the melting temperature of DNA so that it can be rendered single stranded whilst maintaining chromosome morphology. 
70% Formamide solution (made fresh)
4ml	20x SSC
8ml	Distilled water
28ml	Formamide

Steps: 
The slides were immersed in freshly prepared formamide solution for 5 minutes in a fume hood. 
This was followed by treatment with graded ethanol on ice (for 1 minute in each jar).
The slides were then dried on hot plate (for 2 minutes) ready to be probed.

C. FISH probe preparation and hybridization: Each probe (Vysis, Inc. Downers Grove, IL 60515) was prepared, denatured at 70C in a water bath for 5 minutes and then applied (about 20l for a TMA slide) onto the slide and sealed with the glue followed by overnight incubation at 37C for in situ hybridisation in a pre-warmed humidified box for 12-16 hours.

Probe preparation
Vysis LSI dilute (prepared in a sterile eppendorf tube at room temperature)
1l	DNA probe
2l	Distilled water (nuclease free)
7l	LSI hybridisation buffer (Vysis) 

(LSI Hybridization Buffer contains dextran sulfate, formamide and SSC (pH 7.0)).
The mixture was then centrifuged for 1-3 seconds followed by a quick vortex and re-centrifuge.

D. Post Hybridization wash and detection: After overnight incubation, FISH slides were washed strigently in SSC solutions with detergent (for 2 minutes in hot wash at 70C in a waterbath and I minute in room temperature wash) to remove excess unhybridized probe. The slides were then counterstained with DAPI and sealed with nail varnish. These were then examined using a fluorescence microscope or can be stored at 4C in dark.

Hot wash (placed in 70C water bath for atleast 30 min prior to the immersion of slides)
  Ml	0.4x SSC
  Ml	0.3% (v/v) NP-40
Room temperature wash
  Ml	2xSSC 
  Ml	0.1% (v/v)  NP-40
(NP-40 is Nonidet P-40 and is a non-ionic detergent used in the aqueous post-hybridization wash solution)

Steps:
The coverslip was removed and the slide immediately placed into 0.4X SSC/0.3%NP-40 wash tank, agitating the slide for 1-3 seconds. Repeated for the other slides (maximum of 4 each time), and then left all the slides in the Coplin jar for 2 minutes. Care was taken that the coverslips were not removed from several slides before placing any of the slides in the wash bath. The timing of incubation was calculated from the point when the last slide had been added to the wash bath.
The slide was washed in 2X SSC/0.1% NP-40 at room temperature for 5 seconds to 1 minute, agitating for 1-3 seconds as the slide was placed in the bath. 
The slide was allowed to air dry in darkness. 
20 µL of DAPI II counterstain (125ng DAPI/ml in antifade mounting solution) was applied to the slide and a coverslip added.
The slide was viewed under the fluorescence microscope using a suitable filter set. 

Optimization of the technique

The CCND1 amplification was studied for the first time on TMA sections in the Genetics Laboratory, Ninewells Hospital, Dundee., therefore the procedure needed optimization. It was first tested on the pilot TMA which had cores from cancer and normal breast tissue, the latter served as the internal control. The technique worked well on TMA section without any alteration, however, not all cancers could be read optimally to assess the gene amplification. It was decided to subject the TMA sections to varying degree of protease digestion with a view to improve the readability scores. The protease digestion was attempted for durations of 15 min, 20 min, 25min and 30 minutes. TMA subjected to 15 minutes of digestion was no better off than the one with 20 min, rather had low readability score. TMA with 30 min digestion did not add any additional information over and above the one with 25 minutes. The two TMAs sunjected to 20 and 25 minutes of digestion gave the highest readability scores when the information from the two sets was added.

Probes used

a)	LSI Cyclin D1 SpectrumOrange/ CEP11 SpectrumGreen (Vysis) (catalogue no. 32-191039)
This probe was used to detect the amplification of cyclin D1 gene. This is a dual colour DNA probe which hybridizes to band 11q13 (LSI Cyclin D1 SpectrumOrange) and to the centromere, band region 11p11.11q11, locus D11Z1 (CEP11 SpectrumGreen) of human chromosome 11 (Fig-3.8). The LSI (locus specific identifier) Cyclin D1 is approximately 300 kb in size as shown in probe map (Fig-3.9).


Fig-3.8: The arrangement of CCND1 and centromere (CEP11) on chromosome 11.




	
	Fig-3.9: LSI Cyclin D1 probe (300 kb in length).

b)	LSI CCND1 Dual Color Breakapart Rearrangement probe (Vysis, Inc. Downers Grove, IL 60515) (catalogue no. 32-231031)

This was used for the detection of translocations associated with CCND1. The probe hydridizes to the band 11q13 /SpectrumGreen on the 5’ (centromeric) side and SpectrumOrange on the 3’ (telomeric) side of the CCND1 locus breakpoints and the two probes are separated by an approximately 420 kb gap (Fig-3.10) In interphase nuclei, the probe appears as two distinct signals (orange and green) adjacent to each other or fused yellow; while in case of translocation, it shows up as one fusion signal and other fusion signal split into one orange and one green signal (Fig-3.11).



				
Fig-3.10
This probe is a mixture of two probes, the first probe (SpectrumGreen) lies proximal to the CCND1 gene and the second probe (SpectrumOrange) extends distally from the CCND1 gene.








				Fig-3.11
FISH using CCND1 breakapart rearrangement probe demonstrating fused signals on left and the split signal suggesting CCND1 translocation (arrows) on right.



c)	HER2/ neu(ERBB2)/ Alpha satellite 17 (Qbiogene)
The HER2/neu (also called ERBB2) gene encodes a 185 kDa transmembrane cell surface glycoprotein and is a member of the tyrosine kinase family with a high degree of homology to the epidermal growth factor (EGF-R). The Qbiogene probe for HER2/neu is optimized to detect amplification of the HER2/neu gene region. The included Chromosome 17 Alpha Satellite probe serves as an internal control and simultaneously defines the ploidy status of Chromosome 17. The HER2/neu specific DNA Probe is direct-labelled with rhodamine (i.e. appears as red signal), the Chromosome 17 Alpha-Satellite Probe is direct-labelled with fluorescein (i.e. appears as green signal).
(HER-2 amplification was not specifically examined for this thesis. Dr. N. Foster, Clinical Cytogenetics, performed this work and the results were kindly provided by the Department of Genetics to incorporate in this study.)

CCND1

CCND1 amplification was assessed by fluorescence in-situ hybridisation (FISH) using LSI Cyclin D1 SpectrumOrange/ CEP11 SpectrumGreen (Vysis, Inc. Downers Grove, IL) on TMA sections. A readability score of 94% was achieved during the study; a few could not be assessed for gene amplification due to poor digestion, difficult morphology with overlapping cells and/or poor strength of fluorescent signal. The readability scores were substantially improved by probing at least two sections from each TMA, using different time periods for protein digestion (e.g. one section was digested for 20 min and the other for 25 min). The longer time period allowed adequate digestion of those samples that could not be assessed following a shorter period of digestion.

HER2 

HER2 amplification was assessed by FISH using a locus specific probe (Qbiogene Inc., MP Biomedicals Europe, France) on TMA sections, 4μm thick. As with CCND1 FISH, TMA sections underwent protease digestion for 20 and 25 minutes to combat the effects of over and under digestion, before probe hybridisation. 

All HER2 and CCND1 slides were viewed using an Olympus BX51 epi-fluorescence microscope equipped with DAPI, SpectrumGreen™ and SpectrumOrange™ filter cubes. Images were captured using Applied Spectral Imaging acquisition software.


Amplification criteria

Two amplification criteria were employed: ratio and copy number gain. The ratio of orange (CCND1 or Her2) to green (CEP11 or CEP17) signals (PathVysion Her2 assay, Vysis, Inc. Downers Grove, IL) was calculated for all the cases studied. Ratio ≥ 2.2 and < 4.0 was counted as low amplification and ratio ≥ 4.0 as highly amplified. For copy number gain (CNG): CCND1 and HER2 (orange) signals were counted for each of the cases studied and CNG ≥ 8.0 qualified for high level of amplification, while CNG between 4.0 and 8.0 as low level and CNG < 4.0 as not amplified.

For the purposes of statistical analysis, it was considered more appropriate to use absolute levels of HER2 and CCND1 copy number average (CNA) rather than the relative values provided by ratio (HER2/CEP17 and CCND1/CEP11). At least ten non-overlapping nuclei were scored for amplified tumours. For tumours with equivocal amplification, at least 30 nuclei were scored to achieve an average score. All the sections were scored by two independent observers (PGR, Dr. K.Rooney).

Statistical Analysis

Statistical tests were performed using Minitab Release 14.1 (Minitab Inc) and SPSS v13.0 (SPSS Inc, Chicago, IL). The tests used included Fisher’s exact test,  test, and appropriate choice of 2-sample t-test and Mann-Whitney U-test (parametric and non- parametric distributions, respectively) used to compare average NPI values of amplified and non-amplified cancers. The null hypothesis was rejected at α level of 5% () for all analyses.



















CHAPTER-4
RESULTS







Cyclin D1

Cyclin D1 Immunohistochemistry
A total of 99 invasive cancers, from 47 premenopausal and 52 postmenopausal women were studied for expression of cyclin D1. 91/98 cancers stained positive for cyclin D1 expression with scores varying from 1 to 18, while 8 cancers showed no expression. Cyclin D1 overexpression was defined by a score equal to or greater than 6/18 to ensure inclusion of cancers with cyclin D1 labelling index greater than 50% and or staining intensity greater than 1/3 (Fig-4.1). Cyclin D1 overexpression (Fig-1) was observed in 63 out of 99 cancers (63.6%), with comparable distribution in premenopausal (30/47 i.e.64%) and postmenopausal patients (33/52 i.e. 63.4%) (Table-4.1). 










Fig-4.1
Photomicrographs depicting Cyclin D1 expression on immunohistochemistry




Table-4.1
Distribution of cyclin D1 overexpression according to menopausal and estrogen receptor (ER) status. Cyclin D1 was significantly associated with ER expression (p<0.001, Fisher’s exact test).

	Cyclin D1 overexpressed	Cyclin D1 not overexpressed	Total
ER-positive	Premenopausal	28 	9	37
	Postmenopausal	29	10	39
	Total	57 (70%)	19 (30%)	76 (76.7%)
ER-negative	Premenopausal	2 	8	10
	Postmenopausal	4	9	13
	Total	6 (26%)	17 (74%)	23 (23.3%)
Total	Premenopausal	30 (63.8%)	17	47
	Postmenopausal	33 (63.4%)	19	52
	Total	63 (63.6%)	36 (36.4%)	99


From 99 cancers, 76 (76.7%) were ER positive i.e. ER score greater than or equal to 4/18. Among ER positive cancers, 57 (70%) showed cyclin D1 overexpression. Out of 23 ER negative (23.3%) cancers, only 6 cancers (26%) showed cyclin D1 overexpression. Cyclin D1 overexpression was significantly associated with the ER status (p<0.001, Fisher’s exact test) (table-4.1), the odds ratio for cyclin D1 overexpression in ER positive cancer compared to ER negative was 7.9. 

CCND1 amplification

A total of 99 invasive cancers on TMA sections were subjected to FISH to study CCND1 amplification using LSI CyclinD1/CEP11 probe (Vysis). The technique worked well with TMA sections making the procedure economical for research purposes. 93/99 could be analysed giving a readability score of 94%. 6 tumours (4 premenopausal and 2 postmenopausal) could not be assessed due to either poor digestion, or difficult morphology with overlapping cells or poor signals. Out of these 6 tumours, 4 had protein overexpression on IHC and 2 did not.
Of the remaining 93 cancers, 27 (29%) showed CCND1 amplification with CNG ≥ 4.0 (table-4.2) (Figure-4.2); 14/27 (52%) were highly amplified (CNG ≥ 8.0) with an average CNG of 12.9 while 13/27 (48%) exhibited low amplification (4.0 ≤ CNG < 8.0) with an average CNG of 5.4 (table-4.4) (Figure-4.3). CCND1 amplification was significantly associated with protein overexpression (p<0.001, Fisher’s exact test); overexpression was observed in all 27 (100%) amplified cancers compared to overexpression in 31/66 (47%) in the non-amplified group. 











				



Fig-4.2
Fluorescent photomicrographs (100X) of FISH using LSI CCND1/CEP11 probe (Vysis) showing no evidence of CCND1 amplification (above) and multiple red signals with 1-2 green signals per nucleus suggesting CCND1 amplification (below).





	Total number of cancers analysed (IHC& FISH)	Cyclin D1 overexpression	CCND1 amplification
Premenopausal	43	27 (62.7%)	13 (30.2%)
Postmenopausal	50	32 (64%)	14 (26%)
Total	93	59 (63.4%)	27(29.03%)

Table-4.2
Distribution of the cyclin D1 overexpression and CCND1 amplification in pre and post-menopausal patients with breast cancer. 6 cancers could not be analysed on FISH, therefore were excluded from the comparative analysis. Of 93 cancers analysed, 71 were ER positive and 22 were ER negative.

				

	

Fig-4.3
FISH microphotographs depicting high CCND1 amplification (CNG>8.0) on left and low amplification (4.0 ≤ CNG < 8.0) on right.

CCND1 amplification was also significantly associated with the intensity of staining (Fig-4.4) on immunohistochemistry (p<0.001, chi square=25.6, d.f.=1). 67% (18/27) of amplified cancers exhibited an intensity of 3 and 33% (9/27) an intensity of 2, while the non-amplified group showed an intensity of 0,1,2 and 3 in 9%, 33%, 40% and 18% cancers respectively.









					Fig-4.4
CCND1 amplification and cyclin D1 overexpression in the same patient. CCND1 amplification (fluorescent photomicrograph, 100X) demonstrated on FISH using CCND1/CEP11 probe (a) associates with the intensity of staining on immunohistochemistry using cyclin D1 monoclonal antibody (b).


Out of the 27 cancers with gene amplification, 26 were ER positive and only 1 was ER negative. CCND1 amplification correlated significantly with ER status (p=0.003, Fisher’s exact test), the odds ratio of CCND1 amplification in ER positive cancer compared to ER negative was 12.1.

The breakapart rearrangement probe (BA) was also used to study the CCND1 amplification pattern. The amplified cancers appeared as multiple green and orange signals adjacent to each other in the CCND1 amplified cells (Fig-4.5), thus ruling out translocation as possible underlying cause of amplification. Of 93 cancers studied, 22 showed copy number gain (i.e.amplification) on FISH using breakapart probe.




Fig-4.5
FISH using breakapart rearrangement probe on a CCND1 amplified cancer demonstrating all the green and orange signals adjacent to each other.





Summary of results
(data appended in worksheet 1)


			

			







				



The above consort diagram illustrates that cyclin D1 is overexpressed in two-thirds of ER-positive cancer as opposed to only one-third of ER-negative cancer. CCND1 amplification was observed primarily in ER-positive cancers and these accounted for half of the cancers exhibiting protein overexpression. Of the amplified cancers, half had high level of amplification and half with loe level amplification.

Prognostic associations
The ER-positive cancers with cyclin D1 amplification were significantly associated with high tumour grade when compared to the non-amplified group (p=0.005, df=2,  for trend = 7.915). 70% of the amplified cancers were grade 3 and 30% were grade 2, while in the other 2 groups the distribution was 36% grade3, 53% grade 2, 11% grade1 (Table-4.3) (Grade-1 cancers were relatively under-represented in the study group). However, there was no significant association with axillary lymph node status or tumour size.
	Amplified (26/71)	Non-amplified (45/71)
Grade 1	0	5/45 (11%)
Grade 2	8/26 (30%)	24/45 (53%)
Grade 3	18/26 (70%) 	16/45 (36%)

																																														

Table-4.3: Correlation of CCND1 amplified ER-positive cancers with the tumour grade (p=0.005, df=2,  for trend = 7.915).

The mean NPI for the CCND1 amplified cancers was significantly higher at 5.55 (p=0.001, 2-sample t-test) than for the non-amplified patients (4.57). The mean NPI of highly amplified group of cancers was 5.64 and that of low amplified group was 5.3. 
The highly amplified CCND1 had a significantly worse prognostic score (p=0.005, 2-sample t-test) than the low amplification group, when analysed individually against the non-amplified group. No significant difference was found between the mean NPI values of low-amplified and non-amplified patient groups.
										
CCND1 and HER2 amplification

From the 93 patient samples on the TMA, 18 showed Her2 amplification and of these 16 were highly amplified with an average CNG of 26 (Table-4.4). Nine cancers showed co-amplification of HER2 and CCND1
 with a mean NPI of 5.80, compared with a mean NPI of 4.96 for cancers showing only HER2 amplification, however the difference in mean NPI was not statistically significant (p=0.078, 2-tailed t-test). 14 cancers were highly amplified for CCND1 (mean NPI of 5.64) compared to 16 for HER2 (mean NPI of 5.34). Of 93 cancers studied, 15 cancers showed overexpression of HER-2 on IHC. Of these, 11 were amplified, while four were not (three and one were 2+ and 3+ on IHC staining, respectively). Similarly, seven cancers with HER2 amplification did not show overexpression on IHC.
Cancers with HER2 and CCND1 amplification	High-level amplification (CNG ≥8.0)No. of amplified cancers (average CNG)	Low-level amplification (CNG ≥4.0 and <8.0)No. of amplified cancers (average CNG)
CCND1 (27/93)	14 (12.9)	13 (5.4)
Her-2 (18/93)	16 (26.0)	2 (4.3)

Table-4.4: Patterns of amplification for CCND1 and Her-2 in breast cancer.

Lobular vs. Ductal carcinoma
The subset of analysis of types of invasive cancers (lobular vs ductal) did not show any variation in the pattern of cyclin D1 amplification. Of 93 cancers, 8 were lobular type and all were ER-positive. Of 8 lobular cancers, 5 showed ER overexpression (63%) and out of the latter 5, 3 (36%) showed CCND1 amplification.

Association with serum oestrogen levels
Serum oestrogen was measured at two different time points i.e. at diagnosis and at surgery for 30 premenopausal and 33 postmenopausal women. The two time points were aimed at different time points in the menstrual cycle of premenopausal women and postmenopausal women served as the control group. Serum FSH and LH levels measured at the same time confirmed the menopausal status of the women in the study. The breast tissue samples corresponding to the two time points were analysed by immunohistochemistry for expression of cyclin D1. 

33 postmenopausal and 30 pre-menopausal patients had blood samples analysed for hormones (E2, FSH and LH) at two different time points. The average serum E2 levels in premenopausal women were 230 and 172 pmol/l at diagnosis and at surgery respectively with average difference in E2 levels at two points of measurement being 131 pmol/l. This is in comparison with serum E2 levels of 133 and 114 at the two respective time points with an average difference of 28 pmol/l in postmenopausal women. An arbitrary level of difference of 60 pmol/l of serum E2 between the two time points was taken as significant. Of 30 pre-menopausal women, 21 had significantly different E2 levels at two time points and were examined for any difference in protein expression at diagnosis and surgery. Of 33 postmenopausal women, 28 had no significant difference in the E2 levels between the two points of measurement, and these served as control.
No significant association was found between the cyclin D1 expression at the two time points and change in serum oestrogen levels (Spearman’s correlation rank coefficient test) (data as shown in Appendix 3).

Association with p53 score (all cases were analysed irrespective of ER status)
Both cyclin D1 amplification and overexpression were significantly related to lower p53 score (p=0.003, ANOVA test), the mean p53 scores for the three groups being 4.0 (CCND1 amplified and cyclin D1 overexpressed), 3.3 (cyclin D1 overexpressed but CCND1 not amplified) and 8.36 (not overexpressed and not amplified).



Mcm2 and Geminin

Ninety-eight patients with primary invasive breast cancer were studied using tissue microarrays, for expression of various proteins by immunohistochemistry (Fig-4.6, 4.7 and 4.8) and labelling index (LI) was calculated for each. The expression of mcm2 and geminin (replication licensing factors) and Ki67 (proliferation marker) was compared with established prognostic marker, NPI and its constituents i.e. tumour grade, axillary lymph node status and tumours size. 









Fig-4.6
Photomicrographs depicting mcm2 expression on immunohistochemistry, with a labelling index of 2 (left) and that of 6 (right).










Fig-4.7
Photomicrographs depicting geminin expression on immunohistochemistry, with a labelling index of 6 (left) and that of 1 (right).










Fig-4.8
Photomicrographs depicting Ki-67 expression on immunohistochemistry, with a labelling index of 1 (left) and 6 (right).



Among the cancers examined, 97/98 cancers stained positive for mcm2 with a mean score of 3.3 for the labelling index, with the majority of the cancers labelling between 2 and 5 (i.e. 5%-80% of cancer cells staining positive). 93/98 cancers stained positive for geminin with mean labelling index score of 2; the majority were in the range of 1 to 3 (i.e. 1%-40%). Similarly, 97/98 cancers stained positive for Ki-67 with a mean score of 2.7 and most cancers ranged from 2 to 4 (i.e. 5%-60%). Increased expression of Ki-67, mcm2 and geminin was observed with increasing tumour grades, the mean values of LI being significantly high for grade 3 tumours compared to grade 1 and grade 2 cancers (p value < 0.05, ANOVA) for all the three proteins (Fig-4.9 and table-4.5). The mean LI of Ki-67 and mcm2 expression are higher than that of geminin (Fig-4.9) and the mean values of mcm2 are higher than that of Ki-67 for each tumour grade. However, the ratio of mcm to Ki-67 and that of geminin to Ki-67 were found to be similar across the different grades in our study. Similar results were obtained for both pre and postmenopausal group of patients when analysed individually.




Fig-4.9: The mean values of labelling indices for the three molecular markers, Ki67, mcm2 and geminin in different grades of invasive breast cancer. The expression of all the three markers is higher with higher grades. Total invasive cancers analysed: 98, Grade 1: 5   grade2: 37   grade 3: 56.

	Grade 1 (n=5)	Grade 2 (n-37)	Grade 3 (n=56)
Ki67 LI	1.6	1.9	3.3
Mcm2 LI	2.0	2.5	3.9
Geminin LI	1.2	1.4	2.4
ER LI	5.6	5.1	3.2
PgR LI	5.4	3.6	2.0
Mcm/Ki-67	1.25	1.3	1.2
Gem/Ki-67	0.75	0.73	0.77

Table-4.5: Mean values of labelling indices for various molecular markers in different grades of invasive breast cancer.

Association with clinical and pathological parameters

Mcm2, geminin and Ki-67 were significantly associated with NPI, the surrogate outcome measure (p<0.0001, Spearman Pearson correlation coefficient) (Table-4.6), the strongest correlation was with mcm2. Linear regression modeling (stepwise) indicates that mcm2 LI, p21, PgR, Geminin and ER status could together explain a 53% variation in NPI, and mcm2 alone can explain a 30% variation in NPI.

Tumour marker	Correlation coefficient
Mcm2	0.47
Geminin	0.42
Ki-67	0.43

Table-4.6: Correlation between proliferation markers and NPI using Spearman’s correlation coefficient.

	
mcm2, geminin and Ki-67 correlated inversely with ER status i.e. higher IHC quickscore and labelling score was evident for these markers in ER negative tumours (student t test, p<0.0001) (table-4.7). Tumours were labelled ER-positive if they score equal to or more than 4 on IHC and ER-negative if score was less than 4.


ER status	              Protein expression (Mean Quickscore)
	Ki-67	Geminin	Mcm2
Positive (ER score>=4)	5.4	3.6	5.3
Negative (ER score<4)	10.5	7.2	9.2



Table-4.7
Association with ER status: The IHC scores of mcm2, Ki-67 and geminin were significantly higher in ER-negative breast cancer as against ER-positive cancers. 


				
Association with other markers

Mcm2 and geminin were positively associated with pathological lymph node metastasis, activated p53 at phosphoserine 392 (using antibody FP3) and inversely associated with PgR (p<0.05, Spearman correlation coefficient) (Table-4.8, 4.9). No correlation was observed with total p53 (using antibody DO-1) and cyclin D1. mcm2 was inversely associated with bcl2 while geminin was positively associated with bax.



  Marker	Correlation coefficient
FP3	0.29
PgR	-0.22
LN status	0.22
Bcl2	-0.22
Tumour grade	0.29

Table-4.8
Correlation between mcm2 and expression of various markers/pathological parameters using Spearman’s correlation coefficient.
				
					
Marker	Correlation coefficient
FP3	0.24
PgR	-0.36
P21	-0.26
Bax	0.23
LN status	0.32

Table-4.9
Correlation between geminin and expression of various markers/ pathological parameters using Spearman’s correlation coefficient.

Association with serum oestrogen levels

No significant association was found between the level of  mcm2 expression at the two time points and change in serum oestrogen levels (Spearman’s correlation rank coefficient test) (data as shown in Appendix 3). The geminin expression was studied at one time point only due to the paucity of antibody available, therefore correlation with change in serum oestrogen could not be studied.















p53

p53 immunohistochemistry

A total of 86 invasive cancers, 40 premenopausal and 46 postmenopausal were studied for expression of p53 using antibody DO-1. 65/86 cancers stained positive for p53 expression with quickscores varying from 1 to 18 with a mean score of 5.2, while 21/86 cancers showed no expression. p53 overexpression on immunohistochemistry was defined by a score greater than 4/18. p53 overexpression (Fig-4.10) was observed in 31 out of 86 cancers (36%), with comparable distribution in postmenopausal (17/46 i.e.37%) and premenopausal patients (14/40 i.e. 35%) (Table-4.10). 

From the 86 cancers stained for p53, 68 (79%) were ER positive i.e. ER score greater than or equal to 4/18. Among ER positive cancers, 20 (30%) showed p53 overexpression with an overall mean score of 4 in ER-positive cancers. Out of 18 ER negative (21%) cancers, 11 cancers (61%) showed p53 overexpression with an overall mean score of 10 in ER-negative cancers (Fig-4.11). p53 overexpression correlated significantly with ER-negative cancers (p<0.0001, 2-tailed t-test) (table-4.10).













Fig-4.10
Photomicrographs depicting p53 expression on immunohistochemistry, showing overexpression with a score of 18 on the left (20x magnification) and a score of 2 on the right (40x magnification).



		

Fig-4.11
The distribution of p53 quickscore in ER-positive (left panel) and ER-negative (right hand panel) cancers. p53 overexpression correlated significantly with ER-negative tumours (p<0.0001).


	Numbers of cancers	Mean p53 score
ER-positive	68	4.0
ER-negative	18	10.0
Premenopausal	40	5.0
Postmenopausal	46	5.4

Table-4.10
The mean values of p53 expression (Quickscore) in ER-ve Vs ER+ve cancers and premenopausal vs. postmenopausal patients.



Association with clinical and pathological markers

p53 expression correlated significantly with the tumour grade (p=0.02, ANOVA), the mean Quickscore being significantly higher for grade 3 in comparison with grade 2 and grade 1 cancers (table-4.11).
No significant association was observed between p53 expression and NPI (Nottingham Prognostic Index) and/or axillary lymph node status.



	Number of cancers	Mean p53 score (Quickscore)
Grade 1	5	1.8
Grade 2	30	3.1
Grade 3	51	6.6

Table-4.11
p53 expression was significantly higher in high grade cancers in comparison to low grade cancers.


Association with other molecular markers

p53 protein expression was positively associated with activated p53 at phosphoserine 392 (using antibody FP3) (p<0.0001, Spearman correlation coefficient =0.68).
No significant association was observed between p53 expression and expression of other proteins such as cyclin D1, PgR, bcl2, bax, mcm2, geminin, p21 detected by immunohistochemistry.

p53 expression and serum oestrogen levels

Serum oestrogen was measured at two different time points i.e. at diagnosis and at surgery for 30 premenopausal and 33 postmenopausal women. The two time points were aimed at different time points in the menstrual cycle of premenopausal women and postmenopausal women served as the control group. Serum FSH and LH levels measured at the same time confirmed the menopausal status of the women in the study. The breast tissue samples corresponding to the two time points were analysed by immunohistochemistry for expression of p53. 

33 postmenopausal and 30 pre-menopausal patients had blood samples analysed for hormones (E2, FSH and LH) at two different time points. The average serum E2 levels in premenopausal women were 230 and 172 pmol/l at diagnosis and at surgery respectively with average difference in E2 levels at two points of measurement being 131 pmol/l. This is in comparison with serum E2 levels of 133 and 114 at the two respective time points with an average difference of 28 pmol/l in postmenopausal women. An arbitrary level of difference of 60 pmol/l of serum E2 between the two time points was taken as significant. Of 30 pre-menopausal women, 21 had significantly different E2 levels at two time points and were examined for any difference in p53 expression at diagnosis and surgery. Of 33 postmenopausal women, 28 had no significant difference in the E2 levels between the two points of measurement, and these served as control. No statistically significant difference was observed in p53 expression with change in serum oestrogen levels in premenopausal women (data shown in Appendix 3). 

















CHAPTER-5
DISCUSSION













The aims of this thesis were:
 a) to study the expression of cyclin D1 (at protein and genetic level) and replication licensing proteins (mcm and geminin) in primary breast cancer.
b) to assess the prognostic implications of cyclin D1 and replication licensing proteins (mcm and geminin) in invasive breast cancer. 
c) to elucidate the differences in expression of tumour proteins (p53, cyclin D1) in relation to the internal endocrine environment in pre-menopausal women with breast cancer. 

Patients 

Premenopausal women presenting with primary, previously untreated breast cancer formed the study group and the postmenopausal women with similar presentation formed the control group. The menopausal status was confirmed by serum oestradiol, progesterone, LH and FSH levels. At least 30 patients were recruited from each group and their blood and tumour samples were collected at two time points i.e. at diagnosis (core biopsy) and surgery. This was done to seek evidence for a change, if any, in the expression of molecular markers such as p53 and cyclin D1 with a change in serum oestradiol levels at two different points of menstrual cycle. An additional 15 premenopausal and 20 postmenopausal patients with a tumour sample available from the surgical specimen were included in the study to evaluate the expression of cyclin D1, mcm2 and geminin in primary, previously untreated breast cancer. The recruitment of premenopausal patients proved difficult as many of these women were considered for neo-adjuvant therapy. It was intended to space the two-time points by two weeks in order to achieve a wider difference in the serum oestradiol levels assuming a 28 day menstrual cycle. However, this was achieved only in 70% of the patients because of a) the logistics involved in arranging theatre time, b) individual irregularities of menstrual cycle and c) the pattern of change in serum oestradiol level along the menstrual cycle. As a consequence, only 21/30 (70%) premenopausal women showed a significant change in serum oestradiol levels (i.e.>60 pmol/l) between the two time points. No information could be found in the available literature searched with regards to what should be considered significant differences in serum oestradiol levels in pre or postmenopausal women. A difference upto 40 pmol/l (and an average difference of 28pmol/l) in serum oestradiol level was frequently observed in postmenopausal women in our laboratory. Considering this difference in the control group samples to be logically clinically insignificant, two arbitrary levels of 60pmol/l and 75pmol/l were chosen to be considered as significant for premenopausal patients. Using either of these values, data was analyzed seperately to assess a relationship between the expression of variables studied and change in serum oestradiol levels at the two time points. No significant association was found with either of the two cut-off values. 

Tumour Tissue Microarray (TMA)

TMAs proved to be an efficient tool for high throughput analysis of various molecular markers using immunohistochemistry by significantly reducing cost, time, and burden of slides necessary to accomplish the tests in comparison with whole tissue sections. Moreover, the technique worked equally well (Bubendorf, Kononen et al. 1999; Zaharieva, Simon et al. 2003; Camp, Neumeister et al. 2008) for performing genetic studies using FISH. Initially, it was attempted to perform the study using TMA blocks with upto 2 cores each from the cancer specimens, but only a 55%-65% concordance was found between TMA and whole tissue sections when immunoassayed for ER and PR. Thereafter the concordance was improved to 95% by constructing a repeat TMA with 4-6 cores from each cancer. The earlier studies in the literature suggested that the analysis of two cores was comparable to screening whole tissue sections in more than 90% of cases (Camp, Charette et al. 2000; Gillett, Springall et al. 2000), however recent studies (Sapino, Marchio et al. 2006) are adopting at least 4 tumour cores to ensure adequate representation of breast cancer, given its heterogeneous nature and the possible heterogenous staining of PgR (Zidan, Christie Brown et al. 1997) and p53 (Burge, Chang et al. 2006).

Immunohistochemistry

Breast cancer specimens obtained at two different time points i.e core biopsy at diagnosis and surgical specimen at excisional surgery were studied. These specimens were obtained from the department of pathology archives. Consent to use the tumour samples for the purpose of research had been obtained prospectively from all the patients entered in the study. Tumour microarrays (TMA) were prepared from the surgical specimens in order to facilitate the immunohistochemical staining process in terms of cost and labour. However core biopsies, being thin are not suitable for TMA preparation, therefore had to be studied as whole tissue sections (WTS).  Tissue specimens at the two time points were compared for the expression of various proteins, therefore adequate steps were taken to ensure the comparability of WTS and TMA. 
There is some evidence to suggest that there is discordance in immnunohistochemical receptor assay between core biopsy and surgical specimen, presumably due to differences in specimen fixation (Mann, Fahey et al. 2005). It is disputed in the literature (Mann, Fahey et al. 2005) that the core biopsies, being small undergo thorough fixation process, whilst the surgical specimen is faced with variations in duration of fixation and the degree of penetrance by the fixative. This study was done prospectively, therefore the surgical samples were quickly transported to the laboratory minimizing the delay to fixation, all the specimens were fixed by the pathologists in a standard manner and surgical specimens were thin sliced and dissected to ensure penetration by fixative. 
In order to ensure the comparability of WTS from core biopsy with TMA made from surgical specimen, we undertook pilot study to assess the optimum number of cores required for adequate representation of each cancer on the TMA. The heterogenous nature of the breast cancer was borne in mind by the pathologist whilst assessing the WTS of the surgical specimen in order to decide the sites to obtain the cores for TMA. This enabled us to establish the minimum number of cores (i.e. 4-6) required from each surgical specimen to adequately represent the tumour on TMA, which in turn ensured at least 2-3 readable cores after immunohistochemical staining. High concordance (95%) was achieved for receptor assay (ER and PR) between TMA from surgical specimen and core biopsy by using 4-6 cores in comparison to 65% concordance on using 2 cores from each cancer on TMA.


Instruments used

The TMAs were stained on DAKO autostainer universal staining system and WTS were stained on Dakocytomation TechmateTM. Different instruments were used for staining because TMAs cannot be stained on Techmate while the autostainer takes only 48 slides in one cycle as against 200 slides in Techmate, it would be have been cost and labour intensive to stain WTS on the DAKO autostainer. However the quality of staining of WTS was assessed on the two systems using the same samples and was found to be indistinguishable. The comparability of two different pieces of equipment used was assessed by staining the sections for oestrogen receptor (ER). The quality of staining and immunohistochemistry (IHC) scores obtained on analysis were then compared with that of the routine diagnostic specimen (ER status is analyzed routinely by IHC on all breast cancer specimens).
The use of two different pieces of equipment for comparison of receptor expression at the two respective time points could be criticised to influence the apparent change, despite the adequate steps that were taken to ensure the comaparability. However, no significant change in expression of the various receptors studied (p53, cyclin D1, mcm2) was seen across the two time points.

Reagents used
Chemmate Detection Kit, Peroxidase/DAB, Rabbit/Mouse, DakoCytomation can be used for staining with both DakoCytomation Techmate and Autostainer Instruments while Vectastain Elite ABC kit, Vector laboratories, Burlingame, CA, USA can only be used with Autostainer. The staining of TMA slides were initially tried using both chemmate and vectastain reagents in the autostainer to ensure their comparability. However, there were differences observed in IHC scores on the slides from the same cancer specimen stained using these two different reagents. Therefore, in order to maintain the comparability between whole tissue sections stained on Techmate and TMAs stained in autostainer, all the sections were stained using Chemmate reagents.

Scoring method

The Quickscore method (Detre et al) was used to analyze the expression of the nuclear proteins. The potential drawbacks of the method are that it is semi-quantitative and arranges the labeling indices into relatively broad groups. However this method is good for high throughput analysis being quicker and easy to follow as against the precise fgtycalculation of labelling index. Another method used in a study involved counting the positively stained cells on the printouts of 3-4 high power (HP) fields (Shetty, Loddo et al. 2005), which is essentially a modification of H-score (Andersen 1992). The argument for not following this method was that this is potentially biased given the heterogeneity of breast cancer, as the area of cancer analyzed is selected and therefore, the IHC scores obtained do not represent an average overall score of the specimen. In order to avoid similar potential bias in TMAs particularly when comparing against WTS, at least 4-6 cores were obtained randomly from different tumour blocks of each tumour for adequate representation on TMA. The third sytem, Allred score used in clinical practice for ER and PgR assessment, involves assessing the a) intensity graded from 0-3 as above and b) proportion of brown staining nuclei graded from 0-5 (0  none; 1 = <1/100; 2 = 1/100-1/10; 3 = 1/10-1/3; 4 = 1/3-2/3; 5 = >2/3), and then adding up the two factors. This system is widely used in USA in clinical practice and a score of 3 or more is considered to be positive. The argument to use this cut-off is to include tumours with 1% -10% weakly staining cells for endocrine therapy (Harvey, Clark et al. 1999). Both quickscore and Allred systems correlate well with quantitative enzyme immunoassay (EIA) (Detre, Saclani Jotti et al. 1995; Harvey, Clark et al. 1999) and predict the response to endocrine therapy equally well. These methods are favoured in clinical practice over EIA being cheap, quick and easy to perform.

FISH

FISH for CCND1 amplification worked well with TMA sections making the procedure economical for research purposes (Andersen, Hostetter et al. 2001; Palacios, Honrado et al. 2005; Sapino, Marchio et al. 2006; Tubbs, Swain et al. 2007). Since FISH probes are expensive, the cost of working with TMAs was approximately 1/10th that of the whole tissue sections even allowing for using two different time periods for tumour digestion by protease (during pre-treatment of formalin fixed TMA sections for FISH) to allow for the variation between cancers in optimal experimental conditions. The treatment of the TMA slides was similar to that of whole tissue sections for the procedure, although TMAs demanded more careful handling because small sections are more liable to detach. It was helpful to have 4-6 cores per tumour on TMA in case of loss of some cores during prolonged treatments.
TMA proved to be accurate and reliable compared with whole sections for studying the gene amplification using FISH. The TMA sections were blinded for normal breast tissue, pimary cancer and metastatic cancer (lymph node) in the initial phase of the study and then read; amplification was not seen in normal breast tissue while primary tumours and metastatic tumours showed variable degree of CCND1 amplification ranging from none through low grade to high grade. FISH was performed twice for the same TMA and similar results were obtained on the two sections, the only difference being the readability scores; thus ensuring the reproducibility of the technique.
For gene amplification using FISH, 94.1% were readable on the TMAs; only 6 out of 99 cancers could not be assessed due to poor digestion, difficult morphology with overlapping cells and/or poor strength of fluorescence signal. The readability scores were substantially improved by probing at least 2 sections for each TMA, using different time periods for protein digestion (e.g. one section was digested for 20 min and other for 25 minutes). The longer time-period allowed adequate digestion of those samples that could not be assessed following shorter period of digestion. This modification of pre-treatment increased the readability score from 85% (20 min digestion only) to 94% (20 min and 25 min digestion). This relates favourably to the readability scores in the literature varying between 80-90% (Bhargava, Lal et al. 2004; Sapino, Marchio et al. 2006).







Cyclin D1

The expression of cyclin D1 at the protein level and chromosomal amplification in invasive breast cancer was examined in order to assess its prognostic significance and potential therapeutic implications of cyclin D1 overexpression and/or CCND1 amplification.
Cyclin D1 overexpression at the protein level was seen in 60% of breast cancers in this study. Protein overexpression was associated with gene amplification in about half the cancers and all cancers with gene amplification exhibited protein overexpression in keeping with the literature (Buckley, Sweeney et al. 1993; Gillett, Fantl et al. 1994). Some previous studies (Gillett, Smith et al. 1996; Hwang, Han et al. 2003; Bilalovic, Vranic et al. 2005) have suggested a good prognostic association between protein overexpression and patient outcome in terms of survival and recurrence. No significant association was demonstrated between protein overexpression and NPI score or tumour grade in this study. 90% of cancers overexpressing cyclin D1 in this study were ER positive.

CCND1 amplification was seen in 30% of the cancers studied and 96% of the cancers with gene amplification were ER positive. CCND1 amplified cancers had a high NPI score when compared to the non-amplified cancer, implicating CCND1 amplification as a prognostic variable in breast cancers. The gene amplification also correlated significantly with tumour grade, though no such association was seen with axillary lymph node involvement or tumour size. Studies in the literature have suggested a poor prognostic association for CCND1 amplification in terms of survival and tumour recurrence (Bieche, Olivi et al. 2002; Naidu, Wahab et al. 2002; Jirstrom, Stendahl et al. 2005), however any association with NPI, a surrogate marker for disease outcome, has not been reported so far. Few studies have looked at the prognostic significance of cyclin D1 overexpression and gene amplification in the same group of patients (Naidu, Wahab et al. 2002; Jirstrom, Stendahl et al. 2005). However, a recent study (Jirstrom, Stendahl et al. 2005) has examined these variables concurrently and suggested that both overexpression and amplification (with the latter being a better predictor) are associated with tamoxifen resistance in ER positive breast cancer. It has been shown that cyclin D1 can potentiate ER activity even in the absence of oestrogen, which may give it a carcinogenic potential (Neuman, Ladha et al. 1997; Zwijsen, Wientjens et al. 1997). Therefore, cyclin D1 overactivity becomes functionally relevant in ER positive cancers. Furthermore cyclin D1 overexpression and amplification was strongly associated with ER positive cancers, thereby suggesting a clinical basis for prognostic assessment of cyclin D1 expression in ER positive cancers.
CCND1 amplification correlated significantly with the intensity of staining on immunohistochemistry (Fig-3) as shown by previous studies (Michalides, Hageman et al. 1996; Jirstrom, Stendahl et al. 2005).

To examine the importance of amplification further, CCND1 amplification was grouped into low and high level of amplification. In the absence of established criteria for CCND1 gene amplification, low level amplification was defined as an average copy number ≥4 and <8, and high level amplification as ≥8.0. This identified, for the first time, a strong statistical relationship between high-level amplification and prognosis (NPI; p=0.005) that was not repeated for the low-level amplification group. This difference between high and low CCND1 copy number may reflect an underlying mechanistic difference of amplification between the patient groups. Low-level amplification would be consistent with CCND1 copy number gain attributable to chromosome 11 polysomy (which rarely occurs in breast cancer as confirmed by karyotyping and CGH (Teixeira, Pandis et al. 1994; Wolman, Heppner et al. 1997; Hislop, Pratt et al. 2002; Chin, Teschendorff et al. 2007)  or other structural chromosomal rearrangement such as partial duplication or unbalanced translocation involving 11q13 (Adeyinka, Mertens et al. 1998). By contrast, high-level amplification (CNG ≥8.0) is likely to reflect ‘true’ gene amplification as reported for other oncogenes such as HER2 and N-myc (Benz, Fedele et al. 2006). Our understanding of gene amplification associated with the cytogenetic manifestations of HSR and DM remains incomplete (Dal Cin and Sandberg 1990)). It is widely accepted that DM and HSR are hallmarks of advanced disease and are intimately associated with a chromosomal instability ‘mutator’ phenotype (CIN) (Cahill, Lengauer et al. 1998; Yuen and Desai 2008). As such, HSR and DM represent selectable genetic elements that can amplify many different oncogenes and confer drug resistance in experimental systems (Hogarty, Winter et al. 2002; Albertson 2006; Snijders, Hermsen et al. 2008). It is therefore perhaps not surprising that high CCND1 amplification was associated with poor prognosis in breast cancer.  
Using FISH data for both CCND1 and HER2 we confirmed the lack of additive effect for HER2 and CCND1 co-amplification (Cuny, Kramar et al. 2000; Janocko, Brown et al. 2001; Al-Kuraya, Schraml et al. 2004). The absolute level of copy number gain was lower for CCND1 (average CNG of 12.9) than for HER2 (average CNG of 26), which may reflect underlying differences in the structure and biological nature of the respective amplicons. For CCND1, the pattern of FISH signals in TMA interphase nuclei was more uniform, consistent with a single CCND1 amplicon of HSR (chromosomally integrated) type.  For HER2, the pattern of amplification was more variable, consistent with single or multiple HSR. Although a few cases showed scattered signal (possible DM) the predominant pattern was clearly that of ‘clumped’ signals consistent with HSR. 

Whether HSR or DM in type, ‘true’ gene amplification reflects significant chromosome instability associated with a well-recognised CIN phenotype (Lengauer, Kinzler et al. 1998; Teixeira da Costa and Lengauer 2002). Unfortunately, as much classical cancer cytogenetic literature pre-dates our current molecular understanding of cancer, the underlying genetic targets of these early gene amplification studies remain obscure (Schimke, Brown et al. 1982; Dal Cin and Sandberg 1990).  Renewed research interest in the nature and extent of co-amplified genes within both the HER2 and CCND1 amplicon has identified a number of other contiguous candidate genes (Kauraniemi and Kallioniemi 2006). While such additional FISH and Array-CGH investigations were beyond the scope of present study this clearly suggests a productive area for future research.

High level CCND1 amplification could be used to identify a subset of ER-positive breast cancers that are associated with poor prognosis. Such patients could be offered adjuvant chemotherapy, in keeping with evidence that CCND1 amplified cancers respond poorly to endocrine agents. With the development of CDK4 inhibitors (Soni, O'Reilly et al. 2001; Engler, Furness et al. 2003), targeted therapy against cyclin D1 also looks promising.
mcm2 and Geminin

The expression of mcm2 and geminin and Ki67 was examined in 98 patients with invasive breast cancer using immunohistochemistry and related to clinical and pathological parameters and the Nottingham Prognostic Index (NPI). Increased expression of Ki-67, mcm2 and geminin was observed with increasing tumour grades, the mean values of LI being significantly high for grade 3 tumours compared to grade 1 and grade 2 cancers (p value < 0.05, ANOVA) for all the three proteins. This is consistent with higher-grade tumours containing a larger proportion of cells with proliferative potential and a smaller proportion of cells in an out-of cycle state (Blow and Hodgson 2002). The mean LI of Ki-67 and mcm2 expression are higher than that of geminin (Fig-1), this is in keeping with the published evidence stating that Ki67 and mcm2 are expressed throughout the cell cycle (G1, S, G2 and M phases) while geminin is expressed in S-G2-M phases of cell cycle (Stoeber, Tlsty et al. 2001; Wharton, Hibberd et al. 2004). In addition, the mean values of mcm2 are higher than that of Ki-67 for each tumour grade, which is in keeping with the evidence that mcm2 also identifies noncycling cells in G1 phase with a proliferation potential (Wharton, Hibberd et al. 2004). However, the ratio of mcm to Ki-67 and that of geminin to Ki-67 were found to be similar across the different grades in our study in contrast to the published literature that observed a decrease in mcm/Ki67 ratio and an increase in geminin/Ki-67 ratio with increasing grades of breast cancer (Shetty, Loddo et al. 2005). The similar Mcm: Ki-67 and geminin: Ki-67 ratios suggest that in tumours of different grades, the cycling cells spend a similar amount of time in the different cell cycle phases. Therefore G1 transit time is likely to be similar in the different tumour grades, with the primary difference being that high grade tumours have an increased proportion of in-cycle cells. 
mcm2, geminin and Ki-67 all correlated significantly with increasing NPI ((a surrogate marker for survival) and in keeping with that, inversely with ER and PgR status, thereby suggesting an association with poor prognosis with these replication licensing variables. The strongest association with NPI was observed with mcm2 confirming the published evidence (Bukholm, Bukholm et al. 2003; Gonzalez, Pinder et al. 2003; Gonzalez, Tachibana et al. 2004; Shetty, Loddo et al. 2005). Since no association was found with the tumour size, the association with NPI is predominantly the effect of change in tumour grade, and axillary lymph node status to a lesser extent.
A weak association was seen for mcm2 and geminin with activated p53 (FP3), although total p53 (DO-1) did not show any association with either replication licensing protein. Though the association between the replication licensing proteins and p53 pathway is poorly understood, it has been suggested that geminin may suppress p53 activity via an inhibitory action on p14ARF, which in turn prevents p53 degradation by Mdm2 (Agrawal, Yang et al. 2006). A novel, but weak, correlation was also observed with the proteins involved in apoptosis i.e. positive correlation between geminin and bax, and a negative correlation between Mcm2 and bcl2. These associations require further evaluation to assess their clinical relevance. 
A change in tumour Ki-67 index (as a marker of proliferation index) following primary systemic therapy has been explored in order to evaluate its potential to predict clinical response to neo-adjuvant therapy. The IMPACT group (Dowsett, Smith et al. 2007) has recently reported a significant association between high Ki-67 expression after 2 weeks of primary endocrine therapy and low recurrence-free survival, in support of previous studies demonstrating a reduction in Ki-67 index with tamoxifen therapy (Clarke, Laidlaw et al. 1993; Dardes, Horiguchi et al. 2000). However the behaviour of Ki-67 index following primary chemotherapy has not been uniform in clinical studies (Billgren, Rutqvist et al. 1999; Chang, Powles et al. 1999; Burcombe, Wilson et al. 2006). While mcm2 has been shown to predict clinical outcome after local definitive therapy in prostate cancer (Meng, Grossfeld et al. 2001), similar studies are yet to be performed in breast cancer.  Replication licensing factors mcm2 and geminin could be considered alongside and compared with Ki-67 as potential markers for disease response in the neo-adjuvant setting in breast cancer (Dowsett, Smith et al. 2007). The studies have shown that the change in Ki-67 expression in response to short-term endocrine therapy in neo-adjuvant setting improves the prediction for recurrence-free survival in comparison to baseline Ki-67 values alone (Dowsett, Smith et al. 2006). This is the basis of currently ongoing CRUK’s POETIC trial (Trial of Perioperative Endocrine Therapy - Individualising Care), wherby the effect of 4 weeks of peri-operative endocrine therapy on ER-positive cancer on disease-free survival is being studied.
While the effect of neo-adjuvant endocrine agents and neoadjuvant chemotherapy on the expression of mcm2 and geminin in breast cancer and the relationship to disease-free survival merits further investigation, these replication licensing factors also have the potential to be used for screening and/or diagnosis of DCIS (ductal carcinoma in situ) and/or breast cancer on cytology specimens similar to cervical cancer screening (Mukherjee, Muralidhar et al. 2007), and for development of targeted anticancer therapies.
This study demonstrates that replication licensing factors; mcm2 and geminin correlate with poor prognosis (ER-negative and high NPI) breast cancers, and therefore merit consideration as poor prognostic markers in breast cancer. Of the three markers, mcm2, geminin and Ki-67, mcm2 exhibits the strongest correlation with the NPI. There is a need for a confirmatory study to quantify this association with disease-free survival in breast cancer patients. Since Ki-67 has been proposed as a marker for disease response in the neo-adjuvant setting (Dowsett, Smith et al. 2007), the effect of neo-adjuvant endocrine and chemotherapy on the expression of mcm2 and geminin in breast cancer and the relationship to disease-free survival merits further investigation.

p53

The expression of p53 in this study confirmed a statistically significant relationship to histological grade and an inverse relationship to oestrogen receptors, while no statistically significant relationship has been reported with axillary node status (Poller, Hutchings et al. 1992; Sirvent, Salvado et al. 1995; Sharma, Ray et al. 1999). Although p53 expression has been found to be related with disease free survival in breast cancer, no association has been observed with NPI (Cengiz-Boduroglu, Irkkan et al. 2003; Jakic-Razumovic, Coric et al. 2005). The similar relationships to various clinico-pathological; tumour grade, lymph node status, NPI markers were observed with p53 expression in our study.  
This study was undertaken with a view to explore a potential change in p53 expression with change in serum oestradiol levels in premenopausal women. This hypothesis resulted from an animal study done in MCF-7 mouse xenograft model that demonstrated an inverse relation between p53 expression and serum oestrogen levels (Thesis: ‘p53 and breast cancer treatment’ by Ziyaie, D. 2001). However, no significant change in p53 expression on immunohistochemistry was observed between two different time-points in menstrual cycle corresponding to significantly different oestradiol levels in premenopausal women in our study. Therefore, we could not elicit any potential tumour-behaviour modifying role of serum oestradiol. This also suggests that the specific mouse model does not reflect the human setting.
There were few issues/difficulties encountered in processing the data. There is no available information in the literature so far with regards to serum oestradiol levels as to what is considered as normal variation in postmenopausal women. An average variation of 28pmol/l in serum oestradiol levels was observed at the two time points in postmenopausal women which were logically thought to be insignificant. Therefore a somewhat arbitrary figure of 60 pmol/l (estimated at the double value of the observed difference in control group) was taken as a significant difference for serum oestradiol levels between two points. 
The assessment of p53 expression at two time points was carried out on whole tissue sections (obtained from core biopsy) corresponding to the time of diagnosis and on TMA that corresponded to the surgical specimen. The two differing methods of assessment were validated for ER expression and found comparable, but not separately for p53.
It was difficult to recruit pre-menopausal patients as a large proportion of these patients are eligible for neo-adjuvant chemotherapy and therefore not suitable for inclusion in this study. Moreover, it is difficult to ascertain where these patients are in their menstrual cycle because of the irregularities in the duration of menstrual cycle and lack of correct information from the patients. Also, the serum estradiol level has a bimodal distribution during a menstrual cycle i.e. there are 2 peaks and each of them have a gradual fall to baseline (Fig-37), which makes it virtually impossible to ensure that the two time points corroborate with peak and trough respectively. Although a two-week gap was aimed at between the diagnosis and surgery, this was not sufficient to ensure a significant difference in E2 levels at two points and therefore 9 of 30 premenopausal women failed to achieve significant difference in E2 levels at two time points. However, this cohort of premenopausal women served as a control (along with postmenopausal women) to the other group. Although no significant difference in p53 expression was seen with change in E2 levels, it could be argued that the number of women thus achieved in the experimental group was too small to reach to any definitive conclusion.




Fig-5.1
Plasma hormone levels throughout the menstrual cycle.


The observation from the MCF7 xenograft model suggesting an inverse relationship between p53 expression and serum oestradiol (Ziyaie 2003) did not hold good in humans, although the numbers tested were relatively small. 










CHAPTER-6
CONCLUSIONS




CCND1	

This study has examined in detail CCND1 copy number on TMAs of primary breast cancer in relation to cyclin D1 protein expression, ER, HER2 amplification, clinical and pathological parameters and prognostic index (NPI) as a surrogate for clinical outcome. CCND1 amplification was identified in 30% of cancers and 26/27 CCND1 amplified cancers were ER-positive. High CCND1 amplification (CNG > 8) was significantly associated with high tumour grade, and higher Nottingham Prognostic Index. This may reflect underlying biological mechanisms with high level amplification associated with classic double minute (DM) or Homogenously Staining Region (HSR) mediated gene amplification as occurs for HER2 in breast cancer. 
The study concluded that high level CCND1 amplification could be used to identify a subset of ER-positive breast cancers that are associated with poor prognosis. Such patients could be offered adjuvant chemotherapy, in keeping with evidence that CCND1 amplified cancers respond poorly to endocrine agents. 

Mcm2 and Geminin

Mcm2-7 and geminin are key components of the replication licensing machinery that regulates DNA replication. Mcm2-7 is required for the initiation of replication but is present throughout the cell cycle, defining cells with proliferative capacity. Geminin represses inappropriate replication licensing during the S-G2-M phases. This study demonstrates that replication licensing factors; Mcm2 and geminin correlate with poor prognosis (ER-negative and high NPI) breast cancers, and therefore merit consideration as poor prognostic markers in breast cancer. Of the three markers, Mcm2, geminin and Ki-67, Mcm2 exhibits the strongest correlation with the NPI. 

p53

In this study, we attempted to explore a potential change in p53 expression with change in serum oestradiol levels in premenopausal women, following the generation of hypothesis from an animal study done in MCF-7 mouse xenograft model. The observation from MCF7 xenograft model suggesting an inverse relationship between p53 expression and serum oestradiol did not hold good in humans, although the numbers tested were small. Even if there is an underlying interaction between p53 and oestradiol in clinical practice, it probably does not translate into an alteration of p53 expression as observed in our study.










Future work

To study the prognostic role of CCND1 amplification in a larger cohort of ER-positive breast cancer in order to validate the findings of this study. The data obtained could potentially support or refute the clinical application of CCND1 amplification as a prognostic marker in breast cancer management. To collect retrospectively the survival and cancer recurrence data for the cohort of patients studied to assess the association of CCND1 amplification with disease-free survival and overall survival.

We have suggested role of CCND1 amplification in identification of high risk ER-positive breast cancers. It would be useful to assess the recurrence rates in such patients, who had endocrine therapy alone in comparison with patients who had chemotherapy and hormone therapy. This would highlight the clinical importance of potential failure of endocrine therapy in the presence of cyclin D1 gene amplification and therefore potentially alter the clinical management. It would be useful to study the expression of proliferation markers i.e. Ki-67 after peri-operative neo-adjuvant endocrine therapy in ER-positive cancers with CCND1 amplification to assess the responsiveness to endocrine therapy. This study could be extended on the cancers recruited in POETIC trial.

To assess the prognostic role of mcm2 and geminin expression in breast cancer, the effect of neo-adjuvant endocrine or chemotherapy on the expression of Mcm2 and geminin alongside Ki67 and the relationship to disease-free survival. There is a trial ongoing to assess the association of change in Ki-67 expression with neoadjuvant hormone therapy in ER-positive patients with breast cancer (POETIC). The samples from the same cohort of patients could be studied for mcm2 and geminin expression and the three tumour markers could be assessed and compared for their prognostic association. A similar study could also be planned for the effect of neoadjuvant chemotherapy in ER-negative patients on the expression of tumour markers.
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